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ABSTRACT
PARTIAL vs. FULL SUPPORT OF THE HEART WITH A CONTINUOUS-FLOW
LEFT VENTICULAR ASSIST DEVICE: IMPLICATIONS FOR
MYOCARDIAL RECOVERY
Carlo Renato G Bartoli
April 14,2011
INTRODUCTION: Heart failure is a major and growing public health concern. Although
heart failure has been considered an inexorable and progressive disorder, emerging
evidence suggests that some patients may have reversible left ventricular dysfunction.
Indeed, recent reports have documented the potential for myocardial recovery in humans in
response to prolonged mechanical circulatory support with a left ventricular assist device
(LVAD). However, myocardial recovery remains uncommon, and a strategy of unloading
the failing left ventricle with a continuous-flow (non-pulsatile) LV AD has not been
specifically developed to promote favorable myocardial remodeling. As a preliminary
investigation, we developed a bovine model of chronic, ischemic heart failure and
quantified the effects of different levels of support with a continuous-flow LV AD on
myocardial mechanoenergetics.
METHODS: Normal cows (n=8) and cows with chronic, ischemic heart failure (n=9) were
studied. To induce heart failure, 90 fAm micro spheres were percutaneously injected into the
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left main coronary artery. Heart failure developed over 60 days. In an acute surgery, a
continuous-flow LV AD was implanted and operated at Low Partial Support (~1.5 Llmin
support, aortic valve opening every beat), High Partial Support

(~3

Llmin support, aortic

valve opening every beat) and Full Support (~5 Llmin, aortic valve maintained closed, left
ventricle maximally unloaded). Cardiac and systemic arterial hemodynamics were
measured with flow probes and pressure catheters. Myocardial blood flow was mapped
with 15 !lm fluorescent-labeled microspheres. After termination, molecular and
histological markers of heart failure were quantified.
RESUL TS: In normal animals, increasing levels of non-pulsatile support deranged the
profile of cardiac and arterial hemodynamics. As cardiac workload decreased, myocardial
vascular resistance increased, and myocardial blood flow decreased. The ratio between
blood supply and demand did not change and indicated appropriate coronary autoregulation
and the presence of an intact coronary reserve. Animals with chronic, ischemic heart
failure exhibited hallmark signs of severe left ventricular systolic dysfunction that included
a 50% reduction in ejection fraction, left ventricular dilatation, decreased cardiac output
and arterial pressures, decreased end-organ blood flow, severe myocardial fibrosis,
myocyte hypertrophy, and increased myocardial apoptosis. In animals with chronic heart
failure, increasing levels of non-pulsatile support similarly deranged the profile of cardiac
and arterial hemodynamics. As cardiac workload decreased, myocardial vascular
resistance increased. However myocardial blood flow did not change and indicated a lack
of a coronary reserve. Importantly, during full but not partial support, the ratio between
blood supply and demand improved significantly to levels observed in normal control
animals.

vi

CONCLUSIONS: After the implantation of an LVAD, full but not partial support of the
failing left ventricle with an LV AD normalizes the myocardial blood supply/demand
relationship. In the immediate postoperative period, the left ventricle should be completely
unloaded. Chronic studies are necessary to determine whether a transition to partial
support may prevent myocardial atrophy and fibrosis that is seen with prolonged full
support. Our bovine model of chronic, ischemic heart failure is appropriate for such a
study.
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CHAPTER I

INTRODUCTION

Adult patients with advanced heart failure that is refractory to pharmacological and
electrical resynchronization therapies have a limited prognosis. For select patients, heart
transplantation offers the best opportunity for long-term survival. However, the number
of available donor hearts

(~3,500

annually worldwide) are inadequate to meet the needs

of more than 30,000 patients listed for heart transplantation worldwide each year!. As a
result, cardiac transplant waiting lists have the highest mortality rate (30%) of any of the
solid organ waiting lists

2

•

If a patient decompensates while on a transplant waiting list and he or she is not granted
high-urgency status, or if the rate of decompensation is rapid, limited options exist. If a
patient does receive a donor heart, chronic rejection and sequelae of long-term
immunosupression limit post-transplant survival to 55% at 10 years 3 . Furthermore, many
patients are not considered for transplantation due to age, comorbidities, or even
inadequate insurance coverage. As a result, many patients are being considered for
therapy with a permanent, left ventricular assist device (L VAD). Indeed, over the past
decade mechanical circulatory support therapies have emerged as a standard, long-term
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therapy for adult patients with advanced, intractable heart failure as a bridge to cardiac
transplantation4, a destination therapy4, or a bridge to myocardial recovery5-9.

The recent, widespread success of mechanical circulatory support has ushered in a new
era of cardiovascular medicine in which multiple implantable options exist to treat
advanced heart failure. Currently, more than 20 novel cardiac assist devices are under
development or in clinical trials with nearly a dozen new systems poised to begin clinical
trials during the first half of the decade 1o-25 . Each device entails unique surgical and
physiological considerations and offers benefits and drawbacks for the patient and the
physician. For example, currently available LVADs require extensive, invasive surgery
such as sternotomy or thoracotomy. However, these "full-support" devices are able to
salvage end-stage heart failure patients by replacing cardiac function and reinstating an
adequate circulation. Consequently, full-support devices are reserved as a final treatment
option only for patients with life-threatening heart failure. As such, full-support L VADs
have not been specifically designed to recover a sick heart, and physicians may be
reluctant to refer less-sick patients for an invasive therapy.

In order to expand the role of mechanical circulatory support for the treatment of lesssevere stages of heart failure, investigators and industry partners are miniaturizing
LVADs for less-invasive and earlier therapy. Small devices that are designed to provide
moderate or "partial-support" in heart failure patients with less advanced disease may be
employed before the onset of irreversible myocardial damage and end-organ dysfunction.
It has been speculated that partial unloading of the failing left ventricle will interrupt the

2

progressive hemodynamic deterioration observed in 'heart failure 14 as well as increase
functional capacity and improve quality of life. Partial support initiated in patients with
less severe myocardial damage may increase the rate of myocardial recovery. Although
there is limited data to support these hypotheses, initial clinical results with partial.

.

14 24 26 27

support deVIces are encouragmg . . . .

As mechanical circulatory support gains prevalence in the clinical management of
cardiovascular disease, it is increasingly important to characterize the physiological
response to different devices and mechanical strategies to support the failing heart. Each
new LV AD system unloads the left ventricle by a distinctive mechanism. Pulsatile
devices mimic pulsatile heart function, whereas continuous-flow devices continuously
(and non-physiologically) unload the heart. Full-support devices replace intrinsic cardiac
function, whereas partial-support devices augment native hemodynamics. The diversity
of strategies to support the failing circulation, the anticipated arrival of numerous novel
devices, and the increasing prevalence of patients undergoing long-term mechanical
circulatory support raise important basic physiological and clinical questions.

For example, what is the optimal strategy of support to promote myocardial recovery
with an LV AD? Mounting evidence suggests that full support of the failing left ventricle
with an LV AD can reverse pathologic myocardial remodeling and permit LV AD
explantation in select patients 5-9 . Yet, strategies to promote myocardial recovery with a
full-support LV AD have demonstrated limited success. In fact, the current strategy of
prolonged full support of patients in end-stage heart failure with irreversible myocardial
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damage may actually be detrimental to the cardiovascular system. As the level of
continuous unloading increases, the native workload of the heart decreases 28 . During full
support, cardiac workload is nearly eliminated because native cardiac function is no
longer needed for adequate circulation. As a result, myocyte atrophy29-31 and ventricular
stiffening31 ,32 may occur and preclude myocardial recovery. Therefore, an understanding
of effects of mechanical unloading of the heart on myocardial mechanoenergetics is
needed in order to develop better support strategies to promote myocardial recovery.

It is generally recognized that varying the level of support with an LV AD affects

myocardial workload and coronary blood flow 33 . Yet this relationship has not been well
characterized and the implications of altered workload and coronary blood flow for
myocardial recovery are unclear. As a starting point, characterization of the blood
supply/demand relationship during LVAD support may answer fundamental questions
necessary to begin to develop a protocol to promote myocardial recovery with a
continuous-flow LVAD. The purpose of this dissertation project was to examine cardiac
and arterial hemodynamics, coronary blood flow, and myocardial workload during
varying levels of support with a continuous-flow LVAD 28 . To this end, a bovine model
of chronic heart failure was developed. Continuous-flow LVADs were implanted in
normal calves and calves with chronic, ischemic heart failure. During partial and full
support with a continuous-flow LVAD, hemodynamics and myocardial blood flow were
measured. The data presented within this dissertation document four important findings:
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I)

Left main coronary artery microembolization induced chronic, ischemic
heart failure in calves. A stable and reproducible large-animal model of
chronic heart failure is possible with many phenotypic similarities to clinical
heart failure.

2)

In normal animals and animals with chronic heart failure, full but not partial
support with a continuous-flow LVAD deranged the physiological profile of
pulsatile cardiac and arterial hemodynamics.

3)

In normal animals, neither full nor partial support with a continuous-flow
LVAD affected the myocardial blood supply/demand relationship. However,
in animals with chronic heart failure, full but not partial support normalized
the myocardial blood supply/demand relationship.

4)

Divergent results were observed between normal animals and animals with
chronic heart failure. Normal animals do not reproduce the complex
pathophysiological presentation of chronic heart failure and are not ideal for
validation and proper translation of mechanical circulatory support
strategies into clinical practice.

The major finding of this study is that in the immediate postoperative period after the
implantation of an LV AD, complete unloading of the failing left ventricle will rebalance
the myocardial blood supply/demand relationship. However, full support with a

5

continuous-flow LV AD dramatically changes cardiac and systemic arterial
hemodynamics and may have long-term consequences. Therefore, chronic studies are
necessary to determine whether a transition to partial support may alleviate or prevent
myocardial atrophy and fibrosis that is seen with prolonged full support. Our bovine
model of chronic, ischemic heart failure is appropriate for such a study.

6

CHAPTER II

BACKGROUND AND LITERATURE REVIEW

I. Pulsatility during Mechanical Circulatory Support

Over the past two decades, full-support LV ADs have evolved into a standard therapy for
patients with end-stage heart failure. In 2002, the milestone Randomized Evaluation of
Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial
demonstrated clinical success with pulsatile LVADs as a long-term therapy for end-stage
heart failure patients34 . Subsequently, the United States Food and Drug Administration
(FDA) approved use of the first -generation, pulsatile HeartMate XVE (Figure 1, Left) as
a destination therapy in patients ineligible for cardiac transplantation35 .

More recently, pulsatile LV ADs, which mimic pulsatile cardiac function, have been
replaced by rotary blood pumps, which continuously (and non-physiologically) unload
the left ventricle. In 2008, the FDA approved use of the HeartMate II (Figure 1, Right)
continuous-flow LVAD in patients for bridge-to-transplant therapl6. Such nextgeneration, full-suPPOli rotary pumps are smaller, more reliable, more energy efficient,
and less surgically traumatic to implant. Notably, superior clinical outcomes have been
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established with next-generation continuous-flow devices 37 . Yet continuous-flow
LV ADs do not generate normal pulsatility (Figure 2)28. As a result, a new population of
"pulseless" patients undergoing long-term LV AD support has emerged.
Continuous-Flow LVAD

Pulsatile-Flow LVAD

~~4-XVE

LVAD

Skin
LIM

Vent Adapter
& Vent Flltor

XVE System
Controlle,

Figure 1, Left: A pulsatile HeartMate XVE is shown. First generation pulsatile devices
mimic native cardiac function. However, these devices are large, difficult to implant, and
less reliable for long-term therapy. Right: A continuous-flow (non-pulsatile) HeartMate
II is shown. Second generation continuous-flow devices are smaller, easier to implant,
and operate with excellent durability for prolonged LVAD therapy. However, the nonpulsatile mechanism dramatically alters the circulation of blood.
Maximum Pulsatile FlowLVAD Support

Maximum Continuous Flow LVAO Support
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Figure 2, Left: Full support with a pulsatile LV AD demonstrates a normal pulsatile
arterial pressure. As blood volume is removed from the left ventricle in a phasic manner,
an arterial pulse is generated. Additionally, sufficient preload permits the left ventricle to
eject through the aortic valve, which preserves a normal pulsatile circulation. Right: In
contrast, full support with a continuous-flow LV AD demonstrates a nearly flat arterial
pressure. As blood volume is continuously removed from the left ventricle into the aorta,
insufficient preload prevents ejection of blood through the aortic valve. As a result, left
ventricular pressure never exceeds aortic pressure, the aortic valve remains chronically
closed, and the systemic circulation is non-pulsatile. AoP, aortic pressure; LVP, left
ventricular pressure
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In this patient population, investigators have raised concerns about the effect of chronic,
non-pulsatile blood flow on myocardial and end-organ perfusion, cardiovascular

. outcomes 38 .
·
arc hItecture,
and Iong-term patient

Pulsatility and mechanical stretch of cardiac myocytes, endothelial cells, and vascular
smooth muscle cells are fundamental to cardiovascular homeostasis. On day 26 of
human embryogenesis, the immature fetal heart begins to beat and pump blood through a
rudimentary vascular system

39

.

From this day forward until the last day of life, cardiac

contraction, stroke volume ejection, and cardiac relaxation with one-way valves expose
every cardiovascular cell (and most cells in the body) to rhythmic mechanical forces that
mediate intracellular and extracellular events. Seemingly, pulsatility is a vital component
of normal mammalian physiology.

Indeed, numerous investigators have demonstrated the superiority of pulsatile blood flow
over non-pulsatile flow during short-term and long-term mechanical circulatory support
in experimental models as well as in adult and pediatric patients40-52 . However, despite
the evidence in favor of pulsatile perfusion techniques, a debate still exists as to which
mode of circulatory support is better. A separate set of investigators have reported no
difference between continuous and pulsatile perfusion modes 53 -59 •

Nevertheless, continuous-flow LVADs constitute the current clinical gold standard for
prolonged mechanical circulatory support

37

•

Yet the effect of continuous support of the

left ventricle and redU(~ed pulsatility on cardiac workload, coronary blood flow, and
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regional myocardial perfusion remain largely uncharacterized. During heart failure, the
supply/demand ratio of available oxygen in blood to myocyte workload becomes
unbalanced60 . Likely, appropriate support with an LV AD may rebalance this
relationship, which may have important implications as the initial step toward myocardial
recovery.

10

II. Partial vs. Full Mechanical Unloading of the Failing Left Ventricle

If a patient awaiting a cardiac transplant decompensates and an appropriate organ is not
available, a full-support LV AD may be the only option for survival. Yet many heart
failure patients are not ill enough or have contraindications to placement of a full-support
LV AD. In these patients, the notion of combining the benefits of partial support with a
minimally invasive and short operation without cardiopulmonary bypass may be feasible.

A recent National Heart, Lung, and Blood Institute (NHLBI) mission statement included
the pursuit of long-term hemodynamic support with minimally invasive surgery to
provide moderate levels of mechanical assistance earlier in the progression of heart
failure (NHLBI, Clinical Use of Ventricular Assist Devices Working Group, March 27-

28,2008 Crystal City, VA)61. The long-term benefits of chronic, partial support are
unknown but may soon be partially characterized by ongoing clinical trials 14 . Significant
62
clinical benefits have been predicted that may decrease the number of patients that
require a heart transplant.

For example, a large gap in available therapies exists for patients in NYHA class III heart
failure that have not responded to biventricular pacing. If these patients are transplant
ineligible or have not met hemodynamic and clinical criteria to justify risks and
comorbidities of sternotomy and a full-support LV AD, limited options exist. In these
patients, partial supp0l1 with a less-invasive device is an attractive option. If partial
support is administered early enough, favorable reverse myocardial remodeling may
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restore sufficient native cardiac function and permit explantation of the device 7. This
hypothesis has not been rigorously tested but is conceptually appealing.

Indeed, in rare instances, full support with an LV AD has resulted in myocardial
recovery5-9. In these patients, functional recovery has accompanied favorable changes at
the molecular and histological levels7,63,64. Yet, strategies to promote reverse myocardial
remodeling with a full-support LV AD have demonstrated limited success and myocardial
recovery remains uncommon. As it turns out, prolonged full support of the left ventricle
with a continuous-flow LVAD may produce numerous unfavorable results. For example,
as the level of full-support increases, variation in end-systolic and end-diastolic volumes
diminish and eliminate the native workload of the heart28 . Myocyte atrophy29,30 and
ventricular stiffening 32 may occur and produce a noncompliant ventricular chamber
incapable of sustained, independent function. Simultaneously, complete volume
unloading of the left ventricle decreases peak systolic pressures to the point where the
aortic valve remains chronically closed. As a result, fused valve leaflets, acquired aortic
stenosis, or total occlusive thrombosis of prosthetic aortic valves may occur65 . Excessive
ventricular unloading with an LV AD may also result in suction events and ventricular
collapse, which may trigger episodes of fatal ventricular tachyarrhythmias66, 67.

Of additional concern, during therapy with a full-support LV AD, approximately 30% of
patients develop right ventricular dysfunction68 with an associated mortality rate of
43%69. During left heart failure, full support with an LV AD may abruptly increase
systemic arterial flow, acutely overload the right ventricle, and cause right ventricular
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failure. For these reasons, full support of the left ventricle with a continuous-flow LVAD
may cause adverse consequences and limit myocardial recovery.

Furthermore, patients in NYHA class III or early class IV heart failure with lessadvanced disease may not require full support with an LVAD. Accordingly, rather than
completely unloading the failing heart, earlier and partial unloading may reduce but not
eliminate native ventricular workload, preserve myocardial structure, and prevent
myocyte atrophy and ventricular stiffening. By reducing ventricular workload and
augmenting myocardial blood flow while still allowing the heart to fill and empty over a
controlled range of ventricular volumes, partial support may be an effective strategy not
only to augment hemodynamics but also to promote favorable myocardial remodeling in
hearts with less disease. Importantly, patients with healthier hearts may have a higher
likelihood of myocardial recovery62.

With this strategy in mind, preclinical studies are necessary to determine effects of partial
support on cardiovascular physiology. Therefore, the purpose ofthis dissertation project
was to initiate in vivo, large-animal experiments to characterize the effect of full and
partial support with a continuous-flow LV AD on systemic hemodynamics and the
myocardial blood supply/demand relationship. Our findings have important clinical
utility and may increase the public-health impact of mechanical circulatory support with
next-generation, continuous-flow LVADs.

13

CHAPTER III

FUNDAMENTAL QUESTIONS

I. Phenomenon
Full-support devices constitute the current gold standard for the treatment of end-stage
heart failure with an LVAD. Myocardial recovery with a continuous-flow LV AD is rare,
and effective strategies to facilitate reverse myocardial remodeling have not been
developed. The field of mechanical circulatory support is trending toward miniaturized
LV ADs that can be implanted with minimally invasive surgery and that provide partial
support for earlier therapy in healthier patients. The clinical utility of partial support is
unknown. However, partial support of patients in earlier stages of heart failure may be a
better strategy to promote myocardial recovery.

II. Proposed Concepts
Important hemodynamic differences exist between partial vs. full support of the
cardiovascular system. The effect of continuous unloading of the left ventricle on cardiac
and systemic hemodynamics, myocardial workload, and coronary blood flow is not well
characterized. The effect of partial support with a continuous-flow LVAD on myocardial
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mechanoenergetics is unknown, and the clinical role of partial support is yet to be
defined.

III. Experimental Design
A series of experiments were designed to compare effects of partial vs. full support with a
continuous-flow LV AD on cardiac and systemic hemodynamics, myocardial workload,
and coronary blood flow. In normal animals without cardiovascular pathology,
continuous-flow LVADs were implanted to determine effects of partial support in the
normal cardiovascular system. In parallel, a model of chronic, ischemic heart failure was
developed in calves. Experiments were repeated in the heart failure model to determine
effects of partial support in the failing cardiovascular system.

IV. Hypotheses and Specific Aims
Hypothesis #1: In normal animals, increasing levels of support with a continuous-flow

LVAD will alter the pulsatile cardiac and systemic arterial hemodynamic profile.
Continuous mechanical unloading of the normal left ventricle will reduce left ventricular
but not right ventricular workload and blood flow in a manner dependent on the degree of
support. The left ventricular blood supply/demand relationship will not change.

Aim #1: Characterize and Compare Hemodynamics and Myocardial Blood Flow during

Partial and Full Unloading of the Normal Left Ventricle with a Continuous-Flow LV AD

15

The goals of this aim were to determine how support with a continuous-flow LV AD
affected hemodynamics, cardiac workload, and myocardial blood flow in normal animals.
Regional myocardial blood flow was related to cardiac and arterial hemodynamics.

Hypothesis #2: Coronary microembolization will produce stable and reproducible

chronic, ischemic heat1 failure in calves.

Aim #2: Develop and Characterize a Bovine Model of Chronic Heart Failure

The goals of this aim were to establish and characterize a stable and reproducible model
of microembolization-induced chronic, ischemic heart failure. This model was used to
test the hypothesis of Aim #3.

Hypothesis #3: In animals with chronic heart failure, increasing levels of support with a

continuous-flow LVAD will alter the pulsatile cardiac and systemic arterial
hemodynamic profile. Continuous mechanical unloading of the failing left ventricle will
reduce left ventricular but not right ventricular workload in a manner dependent on the
degree of support. As a result, the unbalanced blood supply/demand relationship in the
chronically hypoperfused myocardium will rebalance.
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Aim #3: Characterize and Compare Hemodynamics and Myocardial Blood Flow during
Partial and Full Unloading ofthe Failing Left Ventricle with a Continuous-Flow LV AD

The goals of this aim were to determine how support with a continuous-flow LV AD
affected hemodynamics, cardiac workload, and myocardial blood flow in animals with
chronic heart failure. Regional myocardial blood flow was related to cardiac and arterial
hemodynamics.

17

CHAPTER IV

Aim #1: PARTIAL vs. FULL SUPPORT OF THE NORMAL LEFT VENTRICLE
WITH A CONTINUOUS-FLOW LVAD

I. Introduction

Ongoing theoretical debate exists regarding the merits and limitations of partial vs. full
circulatory support. With nearly 3,000 patients logged, the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS) recently documented a 1year survival rate of 75% with full-support LVADs7o. Clearly, end-stage heart failure
patients are benefiting from full-support LV ADs. Yet, better clinical outcomes are
necessary before prolonged LVAD support is more widely accepted. For example,
currently approved devices contain parts that wear down such as polymeric valves and
diaphragms or mechanical contact bearings. To counter this limitation and increase
device durability, third-generation, full-support devices include a bearingless,
magnetically suspended impeller that does not wear over time or generate frictional
heat J3 • As a result, many continuous-flow devices have been miniaturized. In patients
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with moderate heart failure, earlier and minimally invasive partial support may preserve a
near-normal pulsatile hemodynamic profile and reduce but not eliminate cardiac
workload.

Partial support with a minimally invasive surgical approach may also expand the
potential patient population for LV AD therapy. As LV ADs are miniaturized, lessinvasive surgical approaches may increase acceptance by physicians who are more likely
to refer patients for minimally invasive therapies 7 ). Earlier intervention in less-sick
patients should increase the public-health impact of mechanical circulatory support.

In our laboratory, preliminary work in a mock circulatory system demonstrated marked
differences in pulsatility, ventricular pressure-volume relationships, and coronary blood
flow during partial vs. full support with a continuous-flow LVAD 72

.

However, in this in

vitro study it was not possible to determine the effect of partial support on regional
myocardial blood flow or the myocardial blood supply/demand relationship. A recent
study in sheep demonstrated that increasing levels of support with a continuous-flow
LVAD progressively decreased myocardial oxygen consumption, and coronary blood
flow did not change
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•

However, the authors did not normalize coronary blood flow to

myocardial oxygen consumption, and the effect on the oxygen supply/demand ratio was
not reported. FurthemlOre, this study was performed in normal animals without
cardiovascular pathology.
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In order to more rigorously characterize the effect of continuous unloading on the
myocardial blood supply/demand relationship, Aim #1 was a first step in understanding
the chronic consequences of full vs. partial support with a continuous-flow LV AD. The
major goal was to examine acute responses in normal animals. Standard indices of
cardiovascular performance and regional myocardial blood flow were measured during
partial and full support of the normal left ventricle. The implication for reverse
myocardial remodeling and myocardial recovery were considered. The results of this
study will help to guide future investigation into acute and chronic effects of continuousflow mechanical circulatory support in large-animal models of chronic cardiac pathology.
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II. Materials and Methods

Animals
Male Jersey and mixed-breed calves (n=8, 126±13 kg) were used. All animals received
humane care and were handled in accordance with National Institutes of Health and
University of Louisville animal care committee guidelines. Experimental procedures
followed the University of Louisville Institutional Animal Care and Usage Committee
approved protocol #08073.

Anesthesia
Animals were pre-anesthetized with Atropine (30 mg) and prepared for acute, non-sterile
surgery. In the operating room, general anesthesia was administered with Isoflurane (35%) and room air. The animal was placed on the operating table in right lateral
recumbency. Tidal volume and respiratory rate were adjusted to maintain arterial oxygen
saturation above 90%. Fluid-filled arterial and venous catheters were placed in the left
carotid artery and jugular vein for blood sampling. A left thoracotomy was performed.
Ribs #4 and #5 were resected. The pericardium was opened. The animal was
anticoagulated with a single bolus of intravenous Heparin (100 units/kg). For the
remainder of the procedure, the activated clotting time (ACT) was maintained above 250
s with additional boluses of Heparin (1,000 to 2,000 units).

Surgical Instrumentation
A single-tip high-fidelity micromanometer catheter (Millar Instruments, Houston, TX)
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was placed in the aorta and a dual pressure-volume conductance catheter (Millar
Instruments, Houston, TX) was advanced from the left atrium across the mitral valve into
the left ventricle for. simultaneous measurement of aortic, left atrial, and left ventricular
blood pressures. A transit-time ultrasonic flow probe (Transonics, Ithaca, NY) was
placed around the pulmonary artery to measure cardiac output. In six animals, a silicone
catheter (7-French, Access Technologies, Skokie, IL) was advanced in the left atrial
appendage chamber for administration of 15 /lm fluorescent-labeled polystyrene
micro spheres as described below. The depth and angle of catheter entry parallel to the
surface of the left atrial appendage ensured that the catheter did not interfere with mitral
valve function.

LVAD Implantation
A continuous-flow LVAD (HeartWare HV AD n=4, Thoratec HeartMate II n=2) was
implanted with cardiopulmonary bypass. The outflow graft was anastomosed to the
descending aorta. The left ventricular apex was cored and cannulated. The device and
outflow graft were de-aired. A transit-time ultrasonic flow probe (Transonics, Ithaca,
NY) was placed around the outflow graft to measure LV AD flow.

Experimental Design
In each animal, blood pressure and flow waveforms were recorded during Baseline
(pump off, outflow graft clamped), Low Partial Support (~1.5 Llmin support, aortic valve
opening every beat), High Partial Support (~3 Llmin support, aortic valve opening every
beat), and Full Support (~5 Limin, aortic valve maintained closed, left ventricle
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maximally unloaded). Baseline and support modes for each device were maintained for
10 minutes each to achieve steady-state conditions prior to collection of 30 second data
sets. During each condition, a single color of fluorescent-labeled micro spheres (5.25
million micro spheres) was injected into the left atrial catheter. Simultaneously, a
reference blood sample was withdrawn from the arterial line at a rate of 15 mllmin for
100 seconds.

Quantification of Microspheres and Regional Myocardial Blood Flow
The microsphere technique enabled the precise measurement of regional blood flow in
vascular beds of interest as follows. In the left ventricle, the micro spheres mixed with the
blood and were ejected into the aorta to disseminate throughout the body to every organ
according to the physiological distribution of blood flow during that experimental
condition. As the micro spheres approached capillaries, they lodged within the smallest
pre-capillary arterioles based on regional tissue blood flow patterns. With the quantity
used, 15 !-lm spheres do not cause ischemia and did not induce pathology73.

The aortic blood sample acted as a reference for later determination of flow in tissues of
interest. The number of counted microspheres in the reference blood sample (known counted with flow cytometry) was compared to the number of micro spheres that lodged
in pre-capillary arterioles and were counted in a tissue sample of interest (known counted with flow cytometry). The ratio between the two sphere counts was equal to the
ratio between the calibrated rate of aortic withdrawal (known - 15 mllmin) and flow in
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the tissue of interest (unknown) and provided accurate determinations of tissue specific
flows in milliliters per minute per gram of tissue (ml/min/g)73, 74.

At the completion of the study, while under anesthesia, euthanasia was performed with a
fatal intravenous bolus injection of Beuthanasia-D Special (l mll5 kg). The heart was
removed. One to two gram tissue sections from the left ventricular free wall, right
ventricular free wall, interventricular septum, and left ventricular epicardium, midmyocardium, and endocardium were collected. Myocardial and reference blood samples
were sent to IMT/Stason Laboratories (Irvine, CA) for automated digestion, counting of
fluorescent microspheres with flow cytometry, and calculation of tissue specific blood
flows in ml/min/g oftissue.

Data Reduction
All transducers were pre- and post-calibrated against known physical standards to ensure
measurement accuracy. Calibration curves for the volume conductance catheter were
constructed using static and dynamic tests pre- and post-experiment. Data were collected
at 400 Hz, signal conditioned, and AID converted for digital analysis using our Good
Laboratory Practices (GLP) compliant data acquisition system75 .

To determine hemodynamic performance during each support mode, pressure and flow
waveforms were used to derive LV AD flow (LV ADF), heart rate (HR), left ventricular
stroke volume (LV SV), pulmonary artery flow (P AF) as an index of cardiac output
(CO), mean left atrial pressure (LAP), left ventricular end-diastolic pressure (L VP end
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diastolic), left ventricular peak systolic pressure (LVP peak systolic), ±dP/dt, aortic systolic
blood pressure (AoPsystolic), aortic diastolic blood pressure (AOPdiastolic), mean aortic
pressure (AoP mean ), and aortic pulse pressure (AOPpulse). Rate-pressure product (HR x
LVP peak systolic), a standard index of cardiac metabolic demand 76 , was calculated.
Myocardial vascular resistance was calculated as AoP mean/region-specific myocardial
blood flow. Hemodynamic variables were calculated on a beat-to-beat basis for each 30
second data set with the Hemodynamic Evaluation and Assessment Research Tool
(HEART) program77 developed in Matlab (Version 6.5, MathWorks, Natick, MA). All
analyzed beats in each data set (approximately 30 to 50 beats/30 second data set) were
averaged to obtain a single representative mean value for each calculated variable.

Statistics
GraphPad, version 4.00 (Prism, La lolla, CA) was used to perform statistical analyses
and plot data. One-way repeated measures ANOVA with Tukey post-test was performed
for each hemodynamic index, region of myocardial blood flow, and myocardial blood
flow normalized to HR x L VP peak systolic to compare Baseline, Low Partial Support, High
Partial Support, and Full Support modes within each animal. All analyses were twotailed, and a p-value<0.05 (95% confidence) was considered statistically significant. All
data are presented as mean±standard error.
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III. Results

Table 1 demonstrated that in normal animals, as the level of support with a continuousflow LV AD increased, the cardiac and systemic arterial hemodynamic profile
progressively changed. An increase in continuous support decreased HR and CO.
Although the difference between Baseline and Full Support were not statistically
different, the reductions were quantitatively large (HR, -16 bpm; CO, -0.9 Llmin).

Left Ventricular Hemodynamics
Left ventricular pressures demonstrated the most robust changes. The progressive
increase in continuous support significantly decreased LAP (p=O. 01), LVPend diastolic
(p<O.OO 1), and L VP peak systolic (p=0.05) with a dose-dependent response. These reductions
were greatest and indicated maximum unloading during Full Support. Smaller reductions
were observed during partial-support modes. Increasing levels of continuous support did
not affect ±dP/dt.

During Full Support, the variation between peak-systolic and end-diastolic pressures
decreased to non-physiologically low values and resulted in chronic closure of the aortic
valve. In this situation, the average LVPpeak systolic (77±11 mmHg) did not exceed the
AoP diastolic (80±6 mmHg). As a result, the aortic valve remained closed, and HR x
LVP peak systolic decreased significantly (p=0.05) to values that are not seen in normal
animals. This finding indicated that unloading the heart with a continuous-flow LVAD
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dramatically reduced myocardial metabolic demands and with a dose-dependent
response.

Arterial Hemodynamics
Systemic arterial pressures demonstrated less robust changes. As continuous support
increased, AoP mean and AOPsystolic did not change. However, during Full Support
AoP diastolic trended toward an increase of nearly 10 mmHg (p=O.ll), and AoP pulse
decreased significantly from 28±8 to 14±11 (p<O.OOOl). In contrast, during partialsupport modes, the arterial pulse pressure was not significantly changed from baseline.

Myocardial Blood Supply/Demand Relationship
In normal animals, continuous support of the left ventricle did not affect right ventricular
myocardial vascular resistance or blood flow. However, in the left ventricle and
interventricular septum, increasing levels of continuous support reduced the cardiac
workload, increased myocardial vascular resistance (Table 2), and decreased regional left
ventricular blood flow (Table 3) with a significant dose-dependent response. Changes in
vascular resistance and blood flow in the epicardial region demonstrated that the coronary
arteries and large coronary arterioles were participating in observed changes.

To characterize the relationship between myocardial blood supply/demand, regional
myocardial blood flow was normalized to HR x L VP peak systolic. Increasing levels of
continuous support did not alter the ratio between left ventricular myocardial blood flow
and left ventricular workload (Table 4). A baseline value of 0.0085
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n=8
AN OVA p-value

LVADF

(L/min)
p<O.OOOl

0.0:1:0.0
Baseline
1.8:1:0.2*
Low Partial Support
High Partial Support 3.3:1:0.3*t
5.2:1:0.6*H
Full Support

HR
LV SV
PAF
LAP
LVP onddlulollc LVP ....k.ystoIlc +dP/cIt
-dP/cIt HR x LVPpuksystoHc AoP_ AoPsyatoIlc AoP_1c AoPpuI..
(bpm) (ml) (L/mln) (mmHg) (mmHg)
(mmHg) (mmHg/s) (mmHg/s) (bpm x mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
p=0.08 p=0.61 p=0.24 p=O.Ol
p<O.OOl
p=0.05
p=0.68
p=0.34
p=0.05
p=0.93
p=0.68
p=O.l1 p<O.OOOl
86:1:7
72:1:5
71:1:5
70:1:5

99:1:9
108:1:17
106:1: 13
111:1:13

8.6:1:1.1
7.9:1:1.3
7.5:1: 1.1
7.7:1:0.9

16:1:6
15:1:5
15:1:5
12:1:5*

15:1:2
16:1:2
15:1:2
l1:1:2*t*

98:1:5
96:1:6
91:1:8
77:1:11

1,351:1:204
1,517:1:295
1,243:1:241
1,296:1:340

-1,609:1:160
-1,698:1:262
-1,420:1:175
-1,299:1:349

8,627:1:1,085
6,935:1:577
6,463:1:753
5,568:1:971*

84:1:5
83:1:5
83:1:5
86:1:5

100:1:5
98:1:6
95:1:5
94:1:6

71:1:5
69:1:4
73:1:4
80:1:6

28:1:3
29:1:3
22:1:3t
14:1:4*H

N

CO

Table 1: Hemodynamics during partial vs. full unloading of the normal left ventricle with a continuous-flow LVAD. LVADF, left
ventricular assist device flow; HR, heart rate; LV SV, left ventricular stroke volume; PAF, pulmonary artery flow; LAP, left atrial
pressure; LVP, left ventricular pressure; AoP, aortic pressure; *p<O.05, support mode vs. Baseline; tp<O.05, support mode vs. Low Partial
Support; tp<O.05, support mode vs. High Partial Support

ml/min/lOOglbpm·mmHg was established as the myocardial blood supply/demand
relationship in normal animals. Figure 3 summarizes the gross physiological changes
observed during continuous unloading of the normal left ventricle.
n=6

Septum

Epicardium

RV

LV

(mmH!/mt/min/!1

(mmH!/m./mln/v}

AN OVA e-value

e=0.47

e- 0.07

e- 0 .04

e- 0 .07

Baseline
Partial Support
High Partial Support
Full Support

138±28
163±33
235±82
188±67

120±22
151±30
238±86
284±85

114±20
154±28
239±86
304±86*

138±30
173±40
262±98
328±108

Low

!mm!!!/ml/min/l!l (mm!!!/ml/mtn/!!!

Mid-Myocardium

Endocardium

(mm!!!/ml/mtn/!l

(mmH!/ml/min/gl

e- 0 .02

e=0.08

106±20
138±30
199±65
277±75*

133±21
186±41
253±92
352±123

Table 2: Regional myocardial vascular resistance during partial vs. full support ofthe
normal left ventricle with a continuous-flow LVAD. RV, right ventricle; LV, left
ventricle; *p<O.05, Full Support vs. Baseline

n=6
ANOVA Q-value

Baseline
Partial Support
High Partial Support
Full Support

Low

RV

LV

{mllminlsl

{mllminlsl

Q=0.49

e- O.OS

0.60±0.90
0.47±0.08
0.47±0.08
0.49±0.09

0.70±0.10
0.63±0.14
0.S2±0.13
0.43±0.11*

Septum
{mllminlSll

Epicardium Mid-Myocardium Endocardium
{mllminlSll
{mllminlll
{mllminlsl

E-0.07

E-0.07

E=0.01

Q=O.l1

0.73±0.13
0.60±0.13
0.S2±0.14
0.38±0.09*

0.6S±0.13
0.S8±0.14
0.S1±0.14
0.40±0.10

0.80±0.12
0.69±0.14
0.S8±0.14
0.42±0.10*

0.61±0.08
0.S3±0.13
0.47±0.12
0.3S±0.08

Table 3: Regional myocardial blood flow during partial vs. full support of the normal
left ventricle with a continuous-flow LV AD. RV, right ventricle; LV, left ventricle;
*p<O.05, Full Support vs. Baseline

n=6
ANOVA p-value
Baseline
Low Partial Support
High Partial Support
Full Support

LV /HRxLVPpeaksystolic
(ml/min/l00 g/bpm ·mmHg)

Septum/HRxLVPpeak systolic
(ml/min/l00 g/bpm· mmHg)

p=O.72

p=O.91

O.0082±O.OOll
O.0101±O.0017
O.0082±O.0017
O.Ol19±O.0046

O.0085±O.0014
O.0097±O.0017
O.0080±O.0016
O.0093±O.0025

Table 4: Regional myocardial blood supply/demand relationship during partial vs. full
support of the normal left ventricle with a continuous-flow LVAD. LV, left ventricle;
HR, heart rate; LVP, left ventricular pressure
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Figure 3: During support of the normal left ventricle with a continuous-flow LVAD, cardiac
workload decreased, myocardial vascular resistance increased, and myocardial blood flow
decreased. However, the relationship between blood supply and demand did not change and
indicated that an intact coronary reserve and appropriate coronary autoregulation were
present.
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IV. Conclusions
The study of partial vs. full support of the left ventricle with a continuous-flow LV AD
was possible in normal animals. Specifically, in animals without cardiovascular
pathology, 1) a systemic flow reserve was present, 2) full support with a continuous-flow
LVAD deranged pulsatility whereas partial support preserved a more normal pulsatile
profile, 3) as continuous support increased, left ventricular workload and blood flow
decreased, likely as a result of appropriate coronary autoregulation and an intact coronary
reserve. These results will help guide future acute and chronic studies in large-animal
models of cardiac pathology to determine effects of partial vs. full support of the left
ventricle with a continuous-flow L VAD.

Systemic Effects
In normal animals, a systemic flow reserve was present. As the level of support with a
continuous-flow LV AD increased, HR and CO decreased in a dose-dependent manner.
This finding in animals without chronic pathology was not unexpected.

In chronic heart failure, a systemic flow reserve may be absent. Therefore, these results
from normal animals likely cannot be generalized to animals with heart failure.

It is possible that a lack of pulsatile blood flow drops systemic metabolism.

To generate

force, cardiac myocytes consume large quantities of oxygen78 • Similarly, because of
pulsatile stretch and in order to maintain vascular tone, endothelial cells have the greatest
oxidative metabolism of any cells in the body 79. As a result, during the generation and
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regulation of arterial pulsatility, cardiac myocytes, endothelial cells, and vascular smooth
muscle cells metabolize large quantities of oxygen. Therefore, the reduction of cardiac
metabolic demands and arterial pulsatility with a continuous-flow L VAD is likely to drop
total body oxygen requirements and therefore

co.

If this is the case, any level of support

with a continuous-flow LVAD that reduces cardiac workload and arterial pulsatility will
reduce total body oxygen consumption and benefit the heart failure condition.

Effects on the Heart
In the normal heart, full support of the left ventricle with a continuous-flow LVAD
deranged the natural profile of pulsatile cardiac hemodynamics. As continuous support
increased, the maximum pressure generated by the left ventricle dropped below the
arterial diastolic pressure. Insufficient preload was available to eject through the aortic
valve, which did not open. As a result, the workload of the heart was significantly
reduced to values that are not normally observed in bovids. As workload decreased,
myocardial vascular resistance increased, and myocardial blood flow decreased. The
ratio between blood supply and demand did not change and indicated appropriate
coronary autoregulation and the presence of an intact coronary reserve. Substantial
changes in epicardial vascular resistance and blood flow further suggested that the
coronaries were participating in this process and that coronary vasomotor function was
normal.

In chronic heart failure, a coronary flow reserve may be absent6o • Therefore, these results
from normal animals likely cannot be generalized to animals with heart failure.
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Effects on the Arterial System

In normal arteries, full support ofthe normal left ventricle with a continuous-flow LVAD
deranged the natural profile of pulsatile arterial hemodynamics. As continuous support
increased, arterial diastolic pressure trended upwards, and AoP pulse was reduced by half.

In contrast, partial support with a continuous-flow LV AD allowed the aortic valve to
open on every beat. A normal profile of cardiac and systemic arterial hemodynamics
with a near-normal pulse pressure was preserved.

Potential Mechanism for Unfavorable Histological Changes during Prolonged LV AD
Support
Our findings suggest mechanisms by which diminished pulsatility may induce
histological changes within the cardiovascular system during prolonged support with a
continuous-flow LV AD. When cells in the heart and vasculature are exposed to
chronically deranged mechanical forces such as during hypertension, pathological
remodeling may occur. For example, chronic hypertension is well documented to induce
concentric myocardial hypertrophy in the heart as well as tunica medial thickening and
alterations of the collagen/elastin ratio in conduit arteries 8o • During isolated systolic
hypertension, pulse pressures are known to exceed 80 to 100 mmHg and affect cardiac
and arterial tissues. Even the acute blood pressure elevations that are observed in
malignant hypertension may induce acute pathological vascular remodeling that include
hyperplastic arteriolosclerosis and fibrinoid necrosis.
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During continuous unloading of the cardiovascular system, hemodynamics were similarly
deranged but in the opposite direction of hypertension. Full Support reduced the peak
left ventricular systolic pressure to a value below the diastolic arterial blood pressure,
prevented the aortic valve from opening, and reduced the pulse pressure. As a result,
myocardial metabolic demands decreased to values that are not encountered in bovids.
Moderate reductions in metabolic demands are likely important, especially if the goal of
treatment is myocardial recovery. However, the optimal reduction in cardiac metabolism
which allows the heart to rest while maintaining a partial workload has not been
established, and excessive myocardial unloading in which the heart performs too little
workload may induce myocardial atrophy29, 30 and fibrosis 3 !, 32. As a result, it is likely
that the lack of adequate myocardial and arterial stretch during full-support in
continuous-flow LV AD patients may induce architectural changes in cardiovascular
tissues that have long-term consequences, especially ifthe goal is myocardial recovery.
By maintaining pulsatility and a reduced cardiac workload, partial support may attenuate
these effects.

In summary, partial support with a continuous-flow LV AD is feasible and may preserve a
more normal cardiac and systemic arterial hemodynamic profile. Effects of partial
support during heart failure are unlikely to be the same as in normal animals, and the
clinical utility of partial support remains to be determined.
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CHAPTER V

Aim #2: DEVELOPMENT OF A BOVINE MODEL OF CHRONIC,
ISCHEMIC HEART FAILURE

I. Introduction

The development of a stable and reproducible model of chronic heart failure with a low
mortality rate is critical for successful translational research on the clinical treatment of
heart failure. A large-animal model which closely mimics the human cardiovascular
condition (bovine or ovine)81 is necessary for the preclinical testing of implantable
devices as well as to examine (patho )physiological processes associated with mechanical
circulatory support. In terms of anatomical size of the thorax and physiological function
of the cardiovascular system, normal calves have been used for decades as the industry
standard to test safety, performance, and reliability of LV AD systems-phylogenetically
lower species are too small to accommodate implantable cardiac devices. Yet largeanimal models of chronic cardiac pathology have only been used to a limited extent to
investigate mechanical circulatory support82 -84 and adjunct therapies 85 and have not been
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used to determine efficacy or to compare the physiological benefits of different strategies
of mechanical circulatory support. As a result, mechanisms of reverse myocardial
remodeling, myocardial recovery, and pathophysiological responses to mechanical
circulatory support such as ischemic and hemorrhagic stroke 86 , acquired von Willebrand
disease 87, 88, diastolic hypertension57, 58, and gastrointestinal arteriovenous malformations
and bleeding 89 are largely uncharacterized.

Rapid-pacing, volume overload, pressure overload, coronary ligation, microembolization,
and cardiotoxic drugs have been used to induce chronic heart failure in multiple species90 •
Additionally, spontaneous genetic cardiomyopathy exists in Holstein-Fresian cattle91 , 92.
Yet, models of chronic, experimental bovine heart failure 83 , 93 are infrequent in the
literature.

Ischemic cardiomyopathy is the most prevalent etiology of heart failure in human patients
and currently affects more than 3 million people in the United States alone 94 • As such,
large-animal models of chronic, ischemic heart failure are necessary to translate basic
discoveries into clinical utility. Coronary microembolization models of ischemic heart
failure have been developed and validated in sheep 95-99 and in dogsIOo. In these studies,
50 to 120 11m spheres injected into the coronary arteries lodged within pre-capillary
arterioles, produced myocardial ischemia distal to the lodged spheres, and induced a
severe, global left ventricular dysfunction. Over the course of days to weeks, animals
developed a stable and reproducible state of left ventricular failure.
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Similarly, a bovine model of ischemic heart failure is urgently needed for preclinical
studies of mechanical circulatory support. Notably, there is experimental evidence for
the feasibility of such an approach. Injection of large quantities of 6 to 14 !lm plastic
microspheres into the left main coronary arteries in calves resulted in elevated LVP end
diastolic,

reduced SV, CO, mean ejection rate, and left ventricular ejection time, and

produced widespread microinfarcts through the left ventricle 93 • Similarly, daily injection
of 37 to 70 !lm polystyrene microspheres into the left coronary artery of 5 calves resulted
in diminished cardiac function, marked reductions in CO, and significant increases in
LAp s3 •

To study acute and chronic effects of LVADs on clinical, functional, histological, and
molecular markers of myocardial remodeling during heart failure and mechanical
circulatory support, Aim #2 was developed to characterize a bovine model of chronic,
ischemic left ventricular failure. Clinically relevant heart failure was defined by a
reduction of ejection fraction by greater than 40%, changes in ventricular geometry,
hemodynamic imbalance, end-organ hypoperfusion, and histopathological myocardial
changes. Results will assist in guiding future investigation into effects of acute and
chronic mechanical circulatory support in a large-animal model of chronic cardiac
pathology.

The utility of this model extends beyond this project and our laboratory. Our results
contribute a novel and clinically relevant, large-animal heart failure model for other
investigators, government agencies, and industry.
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II. Materials and Methods

Animals
Male Jersey, K-bar, and mixed-breed calves (n=15, 96±8 kg) were used. All animals
received humane care and were handled in accordance with National Institutes of Health
and University of Louisville animal care committee guidelines. Experimental procedures
followed the University of Louisville Institutional Animal Care and Usage Committee
approved protocol #09080.

Anesthesia
Twenty-four hours prior to coronary microembolization, oral Atenolol (50 mg) was
administered to decrease post-micro embolization mortality as previously reported95 •
Animals were pre-anesthetized with Atropine (30 mg) and prepared for strict aseptic
surgery. Prophylactic intravenous Cefazolin (15 to 20 mg/kg) was administered. In the
catheterization laboratory, general anesthesia was administered with Isoflurane (3-5%)
and room air. Tidal volume and respiratory rate were adjusted to maintain arterial
oxygen saturation above 90%. An intravenous catheter was placed in the marginal ear
vein for administration of normal saline (5 to 10 mllkg/hour) to maintain arterial blood
pressure. An intraarterial catheter was placed in the marginal ear artery to monitor
arterial blood pressure. Surface electrocardiographic leads were sutured to the skin in a
lead II configuration. Via modified Seldinger technique, a 7-French introducer sheath
was introduced into the left common carotid artery. The animal was anticoagulated with
a single bolus of intravenous Heparin (100 units/kg).
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Cardiac Catheterization and Baseline Hemodynamics
Under fluoroscopic guidance, a 6-French dual-tip pressure-volume conductance catheter
(Millar Instruments, Houston, TX) was advanced from the carotid artery into the left
ventricle for simultaneous measurement of left ventricular and aortic blood pressures. A
30 second continuous data set was recorded at normal baseline. Approximately 45
minutes after coronary microembolization, this procedure was repeated and a postembolization heart failure baseline data set was recorded.

Cardiac Catheterization and Baseline End-Organ Blood Flow Measurement
Under fluoroscopic guidance, a 6-French pigtail catheter was advanced from the carotid
artery into the left ventricle for injection of 15 flm fluorescent-labeled microspheres. A
single color of fluorescent-labeled microspheres (5.25 million micro spheres) was injected
into the left ventricular chamber. Simultaneously, a reference blood sample was
withdrawn from the carotid sheath at a rate of 15 mllmin for 100 seconds. The
microsphere technique enables the precise measurement of regional blood flow in
vascular beds of interest as previously described in Chapter IV, Section II.

Coronary Catheterization and Microembolization
Intravenous Lidocaine (100 mg) and Amiodarone (150 mg) were administered to prevent
arrhythmia. Under fluoroscopic guidance, a 6-French diagnostic catheter (AL-2) was
advanced from the carotid artery to selectively engage the left main coronary artery.
Correct catheter placement was confirmed by coronary angiography with radio-opaque
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contrast dye (Iothalamate Meglumine, Conray 43, Mallinckrodt, St. Louis MO) as
needed.

To induce global left ventricular ischemia and chronic, ischemic heart failure, 90

~m

polystyrene microspheres suspended in contrast dye were injected into the left main
coronary artery. Real-time observation of electrocardiographic ST-segment changes
were observed and confirmed myocardial ischemia, which accompanied hemodynamic
impairment (Figure 4).
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Figure 4: During a typical microembolization session, 90 !-tm microspheres injected
into the left main coronary artery produced electrocardiographic changes
characteristic of myocardial ischemia. After 45 minutes, ST-segment elevation and
hyperacute, biphasic T-waves indicated severe ischemic myocardial injury. These
changes were accompanied by a 25 mmHg decrease in mean arterial blood pressure
that persisted at 60 days and indicated chronically impaired myocardial functional
capacity. ECG, electrocardiogram
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Over the course of 30 to 45 minutes, multiple small boluses of microspheres were
injected until severe and sustained electrocardiographic changes were accompanied by
impaired hemodynamics. To maintain adequate end-organ blood flow, animals were
supported with continuous infusion of intravenous Phenylephrine, Dobutamine, and
normal saline to effect. Animals typically exhibited a 10 to 15 mmHg rise in LVP end
diastolic.

As such, prior to awakening an intravenous bolus of Lasix (80 mg) was

administered to promote diuresis, mitigate pulmonary effects of elevated left ventricular
filling pressures, and promote recovery and survival.

At the end of the procedure, catheters and sheaths were removed, and percutaneous
access sites were closed and compressed for 30 minutes until hemostasis was achieved.
Animals were recovered.

Clinical Management
Heart rate, respiratory rate, blood pressure, and ECG were monitored for 48 to 72 hours
post-embolization. A constant rate infusion of intravenous Amiodarone (0.5-1.5 mg/min)
was maintained for 12 to 48 hours to prevent tachyarrhythmias. A constant rate infusion
of intravenous Nitroglycerine (800 !-lg/hour) was administered for 24 to 48 hours postembolization. Oral Atenolol (100 mg) was continued twice daily for three days.
Intravenous Cefazolin (15 to 20 mg/kg) was administered for 48 to 72 hours post
embolization. Arterial blood gases and electrolytes were monitored every 2 to 4 hours
for abnormalities. Most animals received intravenous Lasix (0.5 to 2 mg/kg) for
respiratory comfort every 4 to 6 hours based on the animals respiratory pattern and effort.
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Surface ECG leads were removed when the constant rate infusions were discontinued. In
cases of severe heart failure, oral Lasix (0.5 to 4.0 mg/kg) was continued twice daily to
reduce pulmonary edema and respiratory distress. Blood draws were used to monitor
electrolyte and hydration status.

Echocardiography
Transthoracic echo cardiograms were measured at baseline, weekly for 60 days during the
progression of heart failure, and while anesthetized during an acute terminal study with
the chest open. A Phillips iE-33 machine with S8-3 ultrasound probe was used to obtain
2-dimensional echocardiographic recordings. Parasternal views were used to obtain
images. Left ventricular ejection fraction, and end-systolic and end-diastolic volumes
were determined from the apical four-chamber view with a modified Simpson technique
(summation of discs). Target left ventricular dysfunction was defined as a reduction in
left ventricular ejection fraction greater than 40%.

Terminal Study
Sixty days after microembolization, a terminal study was performed to measure the
hemodynamic severity of heart failure and to harvest tissues for histology and molecular
analyses. Anesthesia was induced and maintained as described in Chapter IV, Section II.
The animal was placed on the operating table in right lateral recumbency. Fluid-filled
arterial and venous catheters were placed in the left carotid artery and jugular vein for
blood sampling. A left thoracotomy was performed. Ribs #4 and #5 were resected. The
pericardium was opened. An open-chest echocardiogram was performed.
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A single-tip, high-fidelity micromanometer catheter (Millar Instruments, Houston, TX)
was placed in the aorta and a dual pressure-volume conductance catheter (Millar
Instruments, Houston, TX) was advanced from the left atrium across the mitral valve into
the left ventricle for simultaneous measurement of aortic, left atrial, and left ventricular
blood pressures. A transit-time ultrasonic flow probe (Transonics, Ithaca, NY) was
placed around the pulmonary artery to measure cardiac output. A silicone catheter (7French, Access Technologies, Skokie, IL) was implanted in the left atrial appendage
chamber for injection of 15 /lm fluorescent-labeled polystyrene microspheres. The depth
and angle of catheter entry parallel to the surface of the left atrial appendage ensured that
the catheter did not interfere with mitral valve function.

Experimental Design
In each animal, blood pressure and flow waveforms were recorded for 30 seconds to
determine the hemodynamic severity of heart failure. A single color of fluorescentlabeled micro spheres (5.25 million microspheres) was injected into the left atrial catheter.
Simultaneously, a reference blood sample was withdrawn from the arterial line at a rate
of 15 mllmin for 100 seconds. The microsphere technique enabled the precise
measurement of regional blood flow in vascular beds of interest as described in Chapter
IV, Section II.
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Quantification of Microspheres and End-Organ Blood Flow
At the completion of the study, while under anesthesia, euthanasia was performed with a
fatal intravenous bolus injection of Beuthanasia-D Special (1 mllS kg). The heart was
removed and photographed. The ventricles were sectioned into a multi-level map (Figure
7). One to two gram tissue sections from the left ventricular free wall, right ventricular
free wall, interventricular septum, left ventricular epicardium, mid-myocardium, and
endocardium, kidney, liver, spleen, small bowel, lung, skin, skeletal muscle, brainstem,
cerebellum, and frontal lobe were collected. Tissue samples and reference blood samples
were sent to IMT/Stason Laboratories (Irvine, CA) for automated digestion and counting
of fluorescent microspheres using flow cytometry and calculation of tissue specific blood
flows in mllmin/g of tissue. Regional myocardial blood-flow maps were constructed on a
piece-by-piece basis.

Histology
Triphenyltetrazolium chloride (TTC) staining was performed on gross cross-sections of
hearts to approximate the amount of infarcted myocardium. Microscopic myocardial
histology was performed on left ventricular and right ventricular samples obtained from
heart failure animals (n=9) and compared to myocardium from normal control animals
(n=8). Paraffin-embedded tissues were sectioned at 4 fA,m, de-paraffinized, rehydrated,
and stained. Regional myocardial fibrosis was quantified with Masson's trichrome
staining as the ratio of area occupied by collagen stain to the area of myocardium
sampled 101. Regional myocyte size was determined with FITC-conjugated wheat germ
agglutinin and DAPI (Molecular Probes, Invitrogen, Carlsbad, CA) nuclear co-staining to
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delineate the cell membrane in 100 cross-sectional cells with centrally located nuclei 102 .
Regional total cardiac apoptosis was determined with the DeadEnd Fluorometric TUNEL
System (Promega, Madison, WI), which catalytically incorporates fluorescein-12-dUTP
at DNA strand breaks in cells actively undergoing programmed cell death 102 • Nuclei
were counterstained with DAP!. Myocyte-specific apoptosis was determined with a
combination of Texas Red-conjugated wheat germ agglutinin, TUNEL, and DAPI
staining. Images were viewed with epifluorescence microscopy (Nikon TE2000) and
analyzed with Metamorph Imaging Software. For each histological stain, a minimum of
three fields were analyzed from each myocardial region.

Data Reduction
All transducers were pre- and post-calibrated against known physical standards to ensure
measurement accuracy. Calibration curves for the volume conductance catheter were
constructed using static and dynamic tests pre- and post-experiment. Hemodynamic data
were collected at 400 Hz, signal conditioned, and AID converted for digital analysis
using our GLP compliant data acquisition system75 •

To determine the hemodynamic severity of heart failure, pressure and flow waveforms
were used to derive HR, LVPend diastolic, LVP peak systolic, ±dP/dt , AoP mean , AOPsystolic,
AOPdiastolic, AOPpul se , HR x LVP peak systolic, PAF as an index of CO, and CO/animal weight.
Hemodynamic indices were calculated on a beat-to-beat basis for each 30 second data set
with the Hemodynamic Evaluation and Assessment Research Tool (HEART) program77
developed in Matlab (Version 6.5, MathWorks, Natick, MA). All analyzed beats in each
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data set (approximately 30 to 50 beats/30 second data set) were averaged to obtain a
single representative mean value for each calculated variable.

Statistics
GraphPad, version 4.00 (Prism, La Jolla, CA) was used to perform statistical analyses
and plot data. One-way repeated measures ANOVA with Tukey post-test was performed
to compare weekly echocardiographic measurements. Unpaired student t-tests were
performed to compare acute hemodynamics, chronic hemodynamics, end-organ blood
flow, and histological findings between heart failure animals and normal animals (n=9)15.
Paired student t-tests were used to compare histological findings between the left and
right ventricles within normal control and heart failure animals. All analyses were twotailed, and a p-value<0.05 (95% confidence) was considered statistically significant. All
data are presented as mean±standard error.
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III. Results
Survival, Clinical Findings, and Data Collected
Fifteen animals underwent selective left main coronary artery microembolization.
Hemodynamics in 12 animals were studied at baseline prior to coronary
microembolization and 45 minutes after microembolization. Nine animals survived the
initial embolization period. These animals developed tachycardia, arrhythmias, murmurs,
tachypnea, chronic coughing, and dyspnea on exertion. Serial echocardiography was
performed weekly until termination. Of the nine animals, eight survived 60 days at
which time an elective, terminal study was performed to measure the hemodynamic
severity of heart failure, measure end-organ blood flow, and collect tissues.

Echocardiography
Target severity of chronic heart failure (approximately 40 % reduction in ejection
fraction) was achieved in eight animals. Figure 5 demonstrates M-Mode images at
baseline (A) and 60 days after left main coronary microembolization (B) in the same
animal. Increased heart rate, hypokinetic left ventricular wall motion, and marked
dilatation of the left ventricular chamber are noted.

Left ventricular ejection fraction decreased in all animals (Figure 5 C) from a baseline
conscious value of 81±5% to a final conscious value of 43±13% (p<O.OI vs. baseline)
and final anesthetized value of 29±1O% (p<0.05 vs. final conscious). Left ventricular
end-diastolic and end-systolic volumes increased in all animals (Figure 5 D) from
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baseline values of 115±45 ml and 22±1O ml to final values of 173±28 ml (p<0.05 vs.
baseline) and 101±53 ml (p<0.01 vs. baseline), respectively.

A

.... Embollized Awake (n=9)
Gl Embollzed Anesthetized (n=8)
"p<O.01 vs. baseline (8)
100
tp<O.05. day 63 vs. terminal ane

-c
'Heart Failure (60 Days)

eli.zed (T)

90

B

- End-Oiastolic
"' End-Systolic
'p<O.05 vs. baseline (8)

o

14

B

14

28

42

56

28
42
Day

66

T

70

Day

Figure 5 A, B: M-mode images at baseline and 60 days after coronary microembolization
in the same animal. Left ventricular dilatation and systolic dysfunction are present. C:
Coronary microembolization reduced the left ventricular ejection fraction by
approximately 50%. D: End diastolic and end-systolic left ventricular dilatation was
present.

Acute and Chronic Hemodynamics
Table 5 demonstrates hemodynamic variables measured at baseline and 45 minutes after
left main coronary microembolization. Hallmark hemodynamic changes associated with
systolic dysfunction were noted despite aggressive pharmacological support of
hemodynamics. A significant increase in LVP end diastolic (p<O.OOO 1) was accompanied by
a significant decrease in -dP/dt (p=O.04) and trends toward decreased LVP peaksystolic
(p=O.07), AoP mean (p=O.l4), AOPsystolic (p=O.09), and AOPdiastolic (p=0.20).
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Table 6 demonstrates hemodynamic variables measured at 60 days after the induction of
heart failure. When compared to normal calves of smaller size (n=9, mean: 76.1 kg)IS,
calves that underwent coronary microembolization exhibited hemodynamic changes
associated with left ventricular dysfunction. A trend toward a compensatory tachycardia
accompanied significantly decreased LVP peaksystolic (p=0.008), -dP/dt (p<O.OOI), AoP mean
(p<0.002), AOPsystolic (p<0.002), AOPdiastolic (p=0.004), and CO/weight (p<0.001). A
change in L VP end diastolic did not occur and may have been due to ongoing diuresis used to
treat respiratory distress associated with pulmonary edema.
Baseline Post-Embolization (45 min)
(n=12)
p-value
{n=12}
61±4
66±3
0.37
HR (bpm)
<0.0001
15±1
23±2
LVP end diastolic (mmHg)
'95±3
106±8
0.07
LVPpeakSysto1ic (mmHg)
1,11:6±230
930±70
+dP/dt (mmHg/s)
0 .35
-1,890±243
-1 ,29'5:1:66
-dP/dt (mmHgls)
<0.05
90±9
80±4
AoPmean (mmHg)
0.14
AOPsysto1iC (mmHg)
106±8
94±4
0.09
AOPdiastoliC(mmHg)
76±966±5
0.20
AOPpuise (mmHg)
31±2
28±2
'0.93
HR X LVPpeaksystolic (bpm X mmHg) 6,567±824
6,306±448
0.74

Table 5: Hemodynamics 45 minutes post-embolization. HR, heart rate; LVP, left
ventricular pressure; AoP, aortic pressure
Baseline
{n=9~

HR (bpm)
LVP end diastolic (mmHg)
LVP peak systolic (mmHg)
+dP/dt (mmHg/s)
-dP/dt (mmHg/s)
AoPmean (mmHg)
A:OPsysto1ic (mmHg)
AOPdiastolic (mmHg)
AOPpulse (mmHg)
HR X LVPpeakSystolic (bpm X mmHg)
CO (Umin)
Weight (kg)
COlWeight (mllmin/kg)

78±4
16±2
103±3
1,252±144
-2,527±306
90±4
105±3
73±4
32±2
.s,014±540

8.1±'O.4
7,8±4
105±5

Heart Failure (60 Days)
p-value
{n=8}
88±7
0.24
17±2
0.68
83±6
<0.'01
1,193±195
0.80
-984±95
<0.001
'62±7
<0.01
78±7
<'0.01
51±6
<0.01
28±3
0.22
7,174±586
0.29
7.4±1.0
130±14
61 ±9

0.47
<0.01
<0.001

Table 6: Hemodynamics 60 days post-embolization. HR, heart rate; LVP, left
ventricular pressure; AoP, aortic pressure; CO, cardiac output
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End-Organ Blood Flow

Figure 6 demonstrates end-organ blood flow in normal and chronic heart failure animals.
Reduced blood flow was noted in nine of ten vascular beds studied. Blood flow
reductions were quantitatively large in the kidneys, lung, brainstem, and frontal lobe, but
were not statistically different in any organ.
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Figure 6: Sixty days after coronary microembolization, end-organ blood flow
decreased systemically. However, blood flow reductions were not statistically
significant in any organ and may have indicated that adequate compensation enabled
animals to maintain end-organ perfusion in the lower range of normal.
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Regional Myocardial Blood Flow

Figure 7 demonstrates gross heart sections and a multi-level, regional myocardial blood
flow map in one animal 60 days after microembolization (A-C). This animal received
the majority of the dose of micro spheres in the left circumflex coronary artery. As such,
a large superior and posterolateral myocardial infarction was noted in the gross heart
specimen. Small infarcts are noted dispersed throughout the left ventricular free wall and
interventricular septum.

The myocardial flow maps and regions of reduced myocardial blood flow corresponded
well with the area of gross infarction. Regional right ventricular and anterior
interventricular blood flow was largely unaffected.

Global myocardial hypoperfusion was noted (Figure 7 D, E). Left ventricular free wall
blood flow decreased significantly from control values in normal animals of O. 79±0.09
mllminlg to 0.34±0.05 mllminlg (p<O.Ol) in heart failure animals. Right ventricular free
wall blood flow tended to decrease from control values in normal animals ofO.69±0.08
mllminlg to 0.50±0.1 0 mllminlg (p=0.17) in heart failure animals. Similar reductions
were noted in the epicardium (p=0.10), mid-myocardium (p<O.Ol), and endocardium
(p<O.Ol).
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F igure 7 A-C: TTC-stained gross heart sections and a multi-level, regional myocardial
blood flow map in one animal demonstrated a large superior and posterolateral
myocardial infarction. The dose of mlcrospheres was injected selectively into the left
circumflex coronary artery. D, E: Global myocardial hypoperfusion was noted in heart
failure animals versus normal control animals.
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Histology
Figure 8 demonstrates the gross and microscopic appearances and percentage of fibrosis

in the left and right ventricles in control and microembolized hearts stained with TTC and
Masson's Trichrome, respectively. The heart of a control animal appeared uniform in
color (Top Left Panel). The left ventricular chamber was small.

One week after left main coronary microembolization, the left ventricle exhibited mild
dilatation and large and diffuse islands of unconsolidated coagulative necrosis (Middle
Left Panel). The right ventricle appeared normal.

Eight weeks after coronary microembolization, the left ventricle exhibited marked
dilatation with free-wall thinning and consolidation of infarcted myocardium (Bottom
Left Panel). Although the right ventricular wall appeared grossly normal, marked right

ventricular dilatation was noted.

Microembolized left vlentricular myocardium contained more fibrosis than normal,
control left ventricle (39±1O% vs. 4±2%, p<O.OOOI). Right ventricular myocardium in
microembolized animals also contained more fibrosis than normal, control right ventricle
(11±5% vs. 6±2%, p<O.05). In microembolized hearts, left ventricular myocardium
contained greater fibrosis than right ventricular myocardium (p<O.OOI).
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Figure 8, Left: Microembolized myocardium exhibited significant coagulative
necrosis at 1 week, and consolidated infarction after 8 weeks. A: Right ventricular
myocardium from a microembolized heart exhibited minimal fibrosis. B: Left
ventricular myocardium from a microembolized heart exhibited diffuse infarction.
Bar Graph: Compared to normal control hearts, microembolized hearts contained
significantly elevated fibrosis globally. 4X, black bar = 1,000 f1.m
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Figure 9 demonstrates myocyte size in the left and right ventricles in control animals and
animals that underwent coronary microembolization. Myocytes in the left ventricle of
rnicroembolized hearts were grossly hypertrophic as compared to left ventricular
2

myocytes in normal, control left ventricle (E vs. C, 343±99 !-lm vs. 146±70 !-lm2 , p<O.Ol)
and right ventricular myocytes in the same animal (E vs. D, 343±99 !-lm2 vs. 205±104
!-lm2 , p<0.05). Myocytes in the right ventricle of microembolized hearts were also
hypertrophic as compared to normal, control right ventricle (D vs. B, 205±104 !-lm2 vs.

Control

A

•

Control (n=8)
Embolized (n=9)

*p<O.01 YS. control
tp<O.05 vs. RV

Heart Failure (60 Days)

Right Ventricle Left Ventricle

Figure 9 A: Significant myocyte hypertrophy was observed in the left and right ventricles
of microembolized hearts as compared to normal control animals. Within
microembolized hearts, left ventricular myocytes were significantly larger than right
ventricular myocytes. B, C: Right and left ventricle from normal control animals. D, E:
Right and left ventricle 60 days after coronary rnicroembolization. 20X, white bar = 200
!-lm
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Figure 10 demonstrates the incidence of total cardiac cell apoptosis in the left and right
ventricles in control and microembolized hearts. The total apoptosis rate in the left and
right ventricles of microembolized hearts was markedly increased as compared to normal,
control left and right ventricle (left ventricle: 0.63±0.41 % vs. 0.12±0.1 0%, p<O.Ol ; right
ventricle: 0.45±0.34% vs. 0.14±0.12%, p<0.05). Within microembolized hearts, the
apoptosis rate in the left ventricle trended toward an increase as compared to the right
ventricle (p=0.08).
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Figure 10, A: Total cardiac apoptosis increased significantly in the left and right
ventricles of micro emboli zed hearts as compared to normal control hearts. B, C: DAPI
co-nuclear stain. D, E: FITC TUNEL+ stain. F, G: DAPI plus FITC overlay. Cyan
nuclei indicate TUNEL+ cells. lOX, white bar = 400 flm
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Figure 11 demonstrates the incidence of myocyte-specific apoptosis in the left ventricle
of control and rnicroembolized hearts. Myocyte apoptosis was markedly increased in
microembolized hearts as compared to normal (0.63±0.41 % vs. 0.12±0.1 0%, p<O.O 1) .
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Figure 11, A: Myocyte-specific apoptosis increased significantly in microembolized
hearts as compared to normal control hearts. B, C: Texas Red-conjugated wheat germ
agglutinin stain. D, E: DAPI co-nuclear stain. F, G: FITC TUNEL+ stain. H, I: Texas
Red plus DAPI plus FITC overlay. Cyan nuclei indicate TUNEL+ cells. I: A single
myocyte undergoing apoptosis is seen in the inset. In the upper right comer, a small nest
ofTUNEL+ cells are not myocytes and may be inflammatory cells in the extracellular
matrix that are participating in ischemic, inflammatory-mediated remodeling. 20X, white
bar = 200 "",m
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IV. Conclusions

We have developed a novel bovine model of chronic, ischemic heart failure.
Specifically, injection of 90 [-tm micro spheres into the left main coronary artery
produced: 1) acute electrocardiographic changes consistent with severe ischemic
myocardial injury, 2) a clinical profile consistent with left ventricular failure, 3) acute and
chronic hemodynamic changes associated with systolic dysfunction, 4) a sustained and
stable 50% reduction in left ventricular ejection fraction, 5) left ventricular dilatation, 6)
reduced regional myoeardial and systemic end-organ blood flow, 7) 40% fibrosis of the
left ventricle, 8) global myocyte hypertrophy, and 9) increased total cardiac and myocytespecific apoptosis. Our results establish the feasibility and validity of a bovine model of
chronic, ischemic heart failure that shares many phenotypic similarities with human heart
failure.

In summary, the calf is the industry standard for preclinical testing of cardiac assist
devices. As such, this clinically relevant model is an appropriate platform to test acute
and chronic (patho )physiological responses to LV ADs and other translational therapies.
This model may prove useful to develop support strategies to specifically promote
reverse myocardial remodeling and myocardial recovery during prolonged mechanical
circulatory support.
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CHAPTER VI

Aim #3: PARTIAL vs. FULL SUPPORT OF THE FAILING LEFT VENTRICLE
WITH A CONTINUOUS-FLOW LVAD

I. Introduction

If combined, the benefits of a full-support device implanted with a minimally invasive
surgical approach may expand the target patient population for myocardial recovery with
an LV AD. Original in silico work suggested that partial support of a failing ventricle
with a continuous-flow LV AD may increase cardiac output and lower ventricular filling
pressures62 . The greatest hemodynamic benefits were predicted for less-dilated and lessdysfunctional hearts. Computer simulations were validated in an acute bovine model of
cardiac dysfunction in which continuous partial support at a rate of 3 Llmin decreased left
atrial pressure by 6 to 7 mmHg and increased cardiac output by greater than 1 Llmin62 .

As LV ADs are miniaturized, limited thoracotomy, subxiphoid access, thoracic keyhole
access, placement of surface devices, or percutaneous implantation may permit earlier
therapy in less sick patients. Minimally invasive implantation may increase acceptance
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by patients and physicians who are more likely to refer patients for less-invasive surgical
therapies 71. As a result, earlier intervention in less-sick patients may increase the publichealth impact of mechanical circulatory support. Additionally, these operative
approaches often do not require cardiopulmonary bypass 103 . As a result, less
postoperative coagulopathy may reduce postoperative bleeding and blood transfusions
which playa role in right ventricular dysfunction and infection with LV ADs 104.
Similarly, early clinical data suggest that partial support does not dramatically increase
cardiac output and right ventricular overload and right ventricular failure are unlikelyl4.

Recently, a number of partial support LVADs have been developed. For example, the
CircuLite Synergy Pocket Micro-Pump (CircuLite Incorporated, Saddle Brook, NJ) is a
small continuous-flow LV AD the size of an AA battery (49 mm, outer diameter 14 mm,
25 g)26. The CircuLit(~ LV AD is implanted via a miniature, right-sided thoracotomy
without extracorporeal circulation and continuously unloads 2.5 to 3.0 Llmin of blood
from the left atrium into the subclavian artery.

Less-invasive devices such as the Synergy pump provide important technical benefits. In
the event of pump thrombosis, device failure, or pump-pocket infection, the device may
be easily and rapidly exchanged through the original infraclavicular incision without
entering the chest. An additional and unique advantage is that the implantation procedure
involves a right-sided thoracotomy in which it is unlikely that adhesions will form in the
anterior mediastinum ,md complicate median sternotomy if heart transplantation is
indicated. A future design that obviates entrance into the thorax will include an inflow
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graft placed percutaneously through the subclavian vein and advanced through the
interatrial septum into the left atrium. As with the current design, the outflow graft will
be sewn to the subclavian artery. With this approach, the need for a thoracotomy will be
eliminated, and the infraclavicular incision will be the only incision necessary to implant
the entire system I 05. This approach will likely further increase acceptance by patients and
referring physicians.

Initial results with the CircuLite device are encouraging. In an ongoing multicenter
·· I tna
. 114' 26 , 105 , ambu Iatory patIents
.
.
on th e transp Iant I'1st WI'th motropeEuropean cImIca
independent NYHA class IIIB or IV A heart failure and preserved end-organ function
demonstrated hemodynamic improvements over a 3-month follow-up (ongoing maximum
support duration of eight months)14, 26,105. Partial hemodynamic recovery included
significant increases in cardiac index from 2.0±0.4 to 2.8±0.6 Llminlm2, an increase in
AoPmean from 67±8 to 80±9 mmHg, and a reduction in pulmonary capillary wedge
pressure from 30±5 to 18±5 mmHg26. N-terminal fragment pro-brain natriuretic peptide
was significantly redueed from 6,452±5,470 to 3,209±2,379 pg/ml105 and suggested a
reduction in myocyte stress. As predicted, right heart failure was not a clinical challenge
with the CircuLite pump. During support, the acute increase in cardiac output ranged
from 1.0 to 1.5 Llmin and did not overload the right ventricle l4 .

These preliminary results in humans suggest that partial support is not only safe but may
also be an effective strategy to support less dysfunctional hearts. These findings
encourage basic scientific investigation to further validate and improve this approach.

61

For example, in the current European trial, implants of the CircuLite pump were
performed primarily to demonstrate long-term safety and efficacy as a bridge-totransplant therapy. As such, this device has not yet been implanted with the specific goal
of myocardial recovery.

Accordingly, experimental studies will be necessary to define the clinical utility of partial
circulatory support for the treatment of early stages of heart failure. A major undertaking
will be to evaluate whether a protocol that includes partial unloading may promote
myocardial recovery and in which patient population(s). As a first step, it will be
important to understand how the left ventricle should be unloaded in preparation for
prolonged partial support. The major goal of Aim #3 was to examine acute responses to
partial vs. full support of the failing left ventricle with a continuous-flow LVAD. The
effect of continuous unloading on the myocardial supply/demand relationship was studied
in animals with chronic, ischemic heart failure. Standard indices of cardiovascular
performance and regional myocardial blood flow were measured during each support
mode. Implications for reverse myocardial remodeling and myocardial recovery were
considered. Results of this study will assist in guiding future investigation into the
chronic effects of continuous-flow mechanical circulatory support in large-animal models
of chronic cardiac pathology.
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II. Materials and Methods

Animals
Male Jersey, K-bar, and mixed-breed calves from Aim #2 that had undergone left main
coronary artery embolization and exhibited signs of chronic, ischemic heart failure (n=9,
130±13 kg) were used. All animals received humane care and were handled in
accordance with National Institutes of Health and University of Louisville animal care
committee guidelines. Experimental procedures followed the University of Louisville
Institutional Animal Care and Usage Committee approved protocol #09080.

Anesthesia
Animals were pre-anesthetized with Atropine (30 mg) and prepared for acute, non-sterile
surgery. In the operating room, general anesthesia was administered with Isoflurane (35%) and room air. The animal was placed on the operating table in the right lateral
recumbency. Tidal volume and respiratory rate were adjusted to maintain arterial oxygen
saturation above 90%. Fluid-filled arterial and venous catheters were placed in the left
carotid artery and jugular vein for blood sampling. A left thoracotomy was performed.
Ribs #4 and #5 were resected. The pericardium was opened. The animal was
anticoagulated with a single bolus of intravenous Heparin (100 unitslkg). For the
remainder of the procedure, the ACT was maintained above 250 s with additional boluses
of Heparin (1,000 to 2,000 units).
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Surgical Instrumentation
A single-tip, high-fidelity micromanometer catheter (Millar Instruments, Houston, TX)
was placed in the aorta and a dual pressure-volume conductance catheter (Millar
Instruments, Houston, TX) was advanced from the left atrium across the mitral valve into
the left ventricle for simultaneous measurement of aortic, left atrial, and left ventricular
blood pressures. A transit-time ultrasonic flow probe (Transonics, Ithaca, NY) was placed
around the pulmonary artery to measure cardiac output. In six animals, a silicone
catheter (7-French, Access Technologies, Skokie, IL) was advanced in the left atrial
appendage chamber for administration of 15

~m

fluorescent-labeled polystyrene

micro spheres. The depth and angle of catheter entry parallel to the surface of the left
atrial appendage ensured that the catheter did not interfere with mitral valve function.

LVAD Implantation
A continuous-flow LV AD (HeartWare HV AD n=4, Thoratec HeartMate II n=5) was
implanted without cardiopulmonary bypass. The outflow graft was anastomosed to the
descending aorta. The left ventricular apex was cored and cannulated. The device and
outflow graft were de-aired. A transit-time ultrasonic flow probe (Transonics, Ithaca,
NY) was placed around the outflow graft to measure LV AD flow.

Experimental Design
In each animal, blood pressure and flow waveforms were recorded during Heart Failure
Baseline (pump off, outflow graft clamped), Low Partial Support (~1.5 Llmin support,
aortic valve opening every beat), High Partial Support (~3 Llmin support, aortic valve
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opening every beat), and Full Support (-5 Llmin, aortic valve maintained closed, left
ventricle maximally unloaded). Heart Failure Baseline and support modes for each
device were maintained for 10 minutes each to achieve steady-state conditions prior to
collection of 30 second data sets. During each condition, a single color of fluorescentlabeled microspheres (5.25 million micro spheres) was injected into the left atrial catheter.
Simultaneously, a reference blood sample was withdrawn from the arterial line at a rate
of 15 mllmin for 100 seconds. The microsphere technique enabled the precise
measurement of regional myocardial blood flow as described in Chapter IV, Section II.

In one animal, ventricular fibrillation occurred prior to the implantation of the LV AD.
Open-chest cardiac massage was performed. Multiple shocks were attempted but
defibrillation was unsuccessful. However, after implantation and operation of the LV AD
at full support for approximately 20 minutes, the animal was successfully defibrillated.
The estimated ischemic time was approximately 60 minutes. Prior to data collection, it
was noted that substantial ST -segment elevation accompanied a coronary hyperemia. As
a result, the regional myocardial blood flow data from this animal was not used.

Quantification of Microspheres and Regional Myocardial Blood Flow
At the completion of the study, while under anesthesia, euthanasia was performed with a
fatal intravenous bolus injection of Beuthanasia-D Special (1 mIlS kg). The heart was
removed. One to two gram tissue sections from the left ventricular free wall, right
ventricular free wall, interventricular septum, and left ventricular epicardium, midmyocardium, and endocardium were collected. Myocardial samples and reference blood
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samples were sent to IMT/Stason Laboratories (Irvine, CA) for automated digestion,
counting of fluorescent micro spheres with flow cytometry, and calculation of tissue
specific blood flows in mllminlg of tissue.

Data Reduction
All transducers were pre- and post-calibrated against known physical standards to ensure
measurement accuracy. Calibration curves for the volume conductance catheter were
constructed using static and dynamic tests pre- and post-experiment. Data were collected
at 400 Hz, signal conditioned, and AID converted for digital analysis using our GLP
compliant data acquisition system75.

To determine hemodynamic performance during each support mode, pressure and flow
waveforms were used to derive LVADF, HR, SV, PAF as an index ofCa, LAP, LVPend
diastolic, L VP peak systolic, :±:dP/ dt, HR x LVP peak systolic, AoP systolic, AoP diastolic, AoPmean,
AoP pulse. Myocardial vascular resistance was calculated as AoP mean/region-specific
myocardial blood flow. Hemodynamic variables were calculated on a beat-to-beat basis
for each 30 second data set with the Hemodynamic Evaluation and Assessment Research
Tool (HEART) program77 developed in Matlab (Version 6.5, MathWorks, Natick, MA).
All analyzed beats in e:ach data set (approximately 30 to 50 beats/30 second data set)
were averaged to obtain a single representative mean value for each calculated variable.
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Statistics
GraphPad, version 4.00 (Prism, La Jolla, CA) was used to perform statistical analyses
and plot data. One-way repeated measures ANOVA with Tukey post-test was performed
for each hemodynamic index, region of myocardial blood flow, and myocardial blood
flow normalized to HR x LVP peak systolic to compare Heart Failure Baseline, Low Partial
Support, High Partial Support, and Full Support modes within each animal. An unpaired
student t-test was perDJrmed to compare the myocardial blood supply/demand ratio
between normal and heart failure animals at baseline and during each level of support.
All analyses were two-tailed, and a p-value<0.05 (95% confidence) was considered
statistically significant. All data are presented as mean±standard error.
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III. Results

Table 7 demonstrates that in animals with chronic heart failure, as the level of support
with a continuous-flow LVAD increased, the cardiac and systemic arterial hemodynamic
profile progressively changed. An increase in continuous support increased CO in a
dose-dependent mann(~r. The observed increases were small and were not quantitatively
different between support modes. HR did not change during LV AD support.

Left Ventricular Hemodynamics
As in normal animals, left ventricular pressures demonstrated the most robust changes.
The progressive increase in continuous support significantly decreased LAP (p=O.02),
LVP end diastolic (p<O.O 1), and LVP peak systolic (p<O.O 1) with a dose-dependent response.
Reductions were greatest and indicated maximum unloading during Full Support.
Smaller reductions were observed during partial-support modes. Full Support
significantly reduced +dP/dt (p<O.OOl) and -dP/dt (p=O.03). However, partial-support
modes did not affect ±dP/dt.

As seen in normal animals, during Full Support the variation between end-systolic and
end-diastolic pressures decreased to non-physiologically low values and resulted in
chronic closure of the aortic valve. In this situation, the average LVPpeak systolic (57±9
mmHg) did not exceed the AOPdiastolic (67±6 mmHg). As a result, the aortic valve
remained closed, and HR x LVP peak systolic decreased significantly (p<O.OO 1) to values that
are not seen in normal animals. This finding indicated that unloading the heart with a
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continuous-flow LVAD dramatically reduced myocardial metabolic demands and with a
response dependent on the degree of support.

Arterial Hemodynamics
Systemic arterial pressures exhibited more robust changes than were observed in normal
animals. As continuous support increased, AOPsystolic did not change. However,
AoP diastolic increased significantly by 16 mmHg (p<O.OO 1) and AoP mean trended toward an
increase of 8 mmHg (p=O.II). AoP pulse did not change during Low Partial Support.
However, during High Partial Support, AOPpulse decreased significantly from 27±3 to
15±2 mmHg (p<O.OOOI), which was comparable to the reduction observed in normal
animals during Full Support. Importantly, during Full Support, the arterial pulse pressure
was significantly reduced from 27±3 to 5±1 mmHg (p<O.OOOI). In contrast, during Low
Partial Support, AoP pulse did not change from Heart Failure Baseline.

Myocardial Blood Supply/Demand Relationship
In animals with chronic heart failure, continuous support of the left ventricle did not
affect right ventricular myocardial vascular resistance or blood flow. However, in the left
ventricle and interventricular septum, increasing levels of continuous support
significantly reduced the cardiac workload, and increased the myocardial vascular
resistance (Table 8) with a dose-dependent response. However, the increase in vascular
resistance was not as pronounced as in normal animals, and regional left ventricular

69

n=8

ANOVA p-value

-....:J

o

Heart Failure Baseline
Low Partial Support
High Partial Support
Full Support

LVADF

(L/mln)
<0.0001

0.0:1:0.0
2.3:1:0.3*
3.7:1:0.4*t
6.2:1:1.1*H

HR

LV SV

PAF

LAP

(bpm) (ml) (L/mln) (mmHg)
0.94 <0.0001 0.19
0.02

86:1:8 89:1:12 7.3:1:0.9
86:1:7 66:1:11* 7.7:1:1.1
85:1:9 48:1:9* 7.6:1:1.1
85:1:7 20:l:5*H 7.9:1:1.3

16:1:2
13:1:2
13:1:3
10:1:2*

LVPond~utoIk-lVP""klYltoIlc ----:j:dP/df-- . -clP/dt

(mmHg)
<0.01

(mmHg)
<0.001

(mmHg/s) (mmHg/s)
<0.001
0.03

19:1:3
16:1:2
15:1:2
12:1:2*

84:1:6
84:1:4
83:1:6
57:1:9*H

1,092:1: 166
1,106:1:216
1,007:1: 185
606:1:68*t;

-1,054:1: 160
-1,050:1:96
-973:1: 140
-635:1:137*t

HR x LVP;"';'kayltollc

(bpm x mmHg)
<0.001

7,013:1:466
7,068:1:500
6,902:1:629
4,558:1:428*H

AoP mOl•

AOPayItoIlc AoP_1c

(mmHg) (mmHg)
0.13
0.37

62:1:7
67:1:5
71:1:7
70:1:6

78:1:7
80:1:5
79:1:8
73:1:7

AOPpul..

(mmHg) (mmHg)
<0.001 p<O.OOOl

51:1:6
57:1:5
64:1:6*
67:1:6*t

27:1:3
22:1:2
15:1:2*t
5:1:1*H

Table 7: Hemodynamics during partial vs. full support of the failing left ventricle with a continuous flow LV AD. LVADF, left ventricular
assist device flow; HR, heart rate; LV SV, left ventricular stroke volume; P AF, pulmonary artery flow; LAP, left atrial pressure; L VP, left
ventricular pressure; AoP, aortic pressure; *p<O.05, support mode vs. Heart Failure Baseline; tp<O.05, support mode vs. Low Partial
Support; tp<O.05, support mode vs. High Partial Support

blood flow did not change (Table 9). Vascular resistance and blood flow in the
epicardial region did not change. Likely, the coronaries and large coronary arterioles
were less responsive than in normal control animals, in which large increases in
epicardial vascular resistance were observed.

n-5

RV

LV

Septum

Epicardium

(mmHg/ml/mln/l!)

(mmHg/ml/mln/l!)

(mmHg/ml/mln/g)

(mmHg/ml/min/g)

(mmHg/ml/min/gl

(mmHg/ml/mln/g)

ANOVA e-value

1'-0.98

12- 0 .04

12- 0.01

12-0. 61

12<0.01

12=0.31

Heart Failure Baseline
Low Partial Support
High Partial Support
FuJI Support

1.75±29
:L67±25
:L75±12
:L67±13

164±20
187±45
206±34
249±25*

136±22
141±17
170±17
194±24*t

160±27
168±29
200±33
194±24

140±21
159±27
172±23
217±20*t

199±52
197±42
252±63
217±20

Mid-Myocardium Endocardium

Table 8: Regional myocardial vascular resistance during partial vs. full support of the failing
left ventricle with a continuous flow LVAD. RV, right ventricle; LV, left ventricle; *p<O.05,
Full Support vs. Heart Failure Baseline; *p<O.05, support mode vs. Heart Failure Baseline;
tp<O.05, support mode vs. Low Partial Support

n=5
ANOVA e-value

Heart Failure Baseline
Low Partial Support
High Partial Support
Full Support

RV
{mllminls}
e- 0 .S1

LV
{ml/min/sl
e- 0 . S5

Septum
{ml/minlgl
O.13

Epicardium
{mllmin/gl
0 .S3

0 . 40±O.O4
O.45±O.O6
O.43±O.O5
OA5±O.03

O.41±O.O4
O.44±0.OS
O.40±O.OS
O.45±O.O3

O.51±O.05
O.52±O.O5
OA4±O.05
OAO±O.05

O.41±0.O2
O.40±O.O6
O.39±0.O6
O.40±O.O5

e-

e-

Mid-Myocardium Endocardium
{ml/min/g}
{ml/min/g}
0 . 1S
O.4S

e-

O.49±0.05
O.49±O.OS
OA6±O.OS
O.35±O.O4

e-

O.39±O.O6
O.40±O.O6
O.35±O.O7
O.32±O.70

Table 9: Regional myocardial blood flow during partial vs. full support of the failing left
ventricle with a continuous flow LVAD. RV, right ventricle; LV, left ventricle

To characterize the relationship between myocardial blood supply and demand, regional
myocardial blood flow was normalized to HR x LVP peak systolic (Table 10). During partial
support modes, the ratio between left ventricular workload and left ventricular
myocardial blood flow did not change. However, during full support the supply/demand
ratio improved significantly in the left ventricular free wall (p=O.04) and interventricular
septum (p<O.01) to values comparable to control values obtained in normal animals.
Figure 12 summarizes the gross physiological changes observed during continuous
unloading of the failing left ventricle.
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Comparison to Normal Animals
Without support, the myocardial blood supply/demand relationship in the left ventricle
demonstrated lower values in microembolized hearts as compared to normal, control
hearts (p=O.06). In normal hearts, support with a continuous-flow LV AD did not change
this ratio. However, in microembolized hearts, this difference decreased with greater
levels of support (Low Partial Support p=O.12, High Partial Support p=0.24, Full Support
p=0.47) and indicated normalization of this relationship toward baseline values.

n=5

LV /HRxLVP peak systolic

Septu m/ H RxLVP peak systolic

(ml/min/l00 g/bpm· mmHg)

(ml/min/l00 g/bpm' mmHg)

p=O.04

p<O.Ol

O.0054±O.0007
O.0064±O.0008
O.0057±O.0007
O.0079±O.0014*

O.0066±O.0009
O.0077±O.0009
O.0066±O.0008
O.0099±O.0013*:f:

ANOVA p-value

Heart Failure Baseline
Low Partial Support
High Partial Support
Full Support

Table 10: Regional myocardial blood supply/demand relationship during partial vs. full
unloading of the failing left ventricle with a continuous flow LV AD. LV, left ventricle;
HR, heart rate; LVP, left ventricular pressure; *p<O.05, Full Support vs. Heart Failure
Baseline; tp<O.05, support mode vs. High Partial Support
Normal Animals

Heart Failure Animals

Cardiac Workload

I

I

Myocardial Vascular Resistance

t

t

Myocardial Flow

I

Flow/Workload

...
t

Figure 12: During support of the failing left ventricle with a continuous-flow LV AD, cardiac
workload decreased, and myocardial vascular resistance increased with a dose-dependent
response. However, myocardial blood flow did not change because diastolic blood pressure
was significantly greater during LV AD support and increased the driving force for coronary
blood flow. As a result, the ratio between blood supply/demand improved to values observed
in normal control animals. These findings suggested that in animals with chronic heart
failure, the heart may have been operating at an insufficient ratio of blood supply/demand,
and a coronary reserve was not present.
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IV. Conclusions
The study of partial vs. full support of the left ventricle with a continuous-flow LV AD
was possible in animals with cardiac pathology. Specifically, in animals with chronic,
ischemic heart failure, 1) a systemic flow reserve was not present, and any level of
support with a continuous-flow LV AD augmented systemic flows, 2) full support with a
continuous-flow LV AD deranged pulsatility, whereas partial support preserved a more
normal pulsatile profile, 3) full but not partial support of the failing left ventricle with an
LV AD normalized the blood supply/demand relationship, 4) divergent results observed in
normal animals vs. heart failure animals suggested that mechanical circulatory support
studies should be conducted in large-animal models of chronic cardiac pathology. These
results will assist to guide future in vivo studies to examine myocardial and arterial
remodeling during chronic partial vs. full support of the heart with a continuous-flow
LVAD.

Systemic Effects
In animals with chronic heart failure, a systemic flow reserve was absent. At any level of
support with a continuous-flow LVAD, CO increased and HR did not change. This
finding in animals with chronic heart failure was not unexpected and suggested that any
level of flow augmentation with a continuous-flow LVAD may improve systemic arterial
blood flow. As such, partial-support with a continuous-flow LV AD in patients with
chronic heart failure may be a successful therapy for patients with hypoperfused end
organs.
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Effects on the Heart
In the failing heart, full support with a continuous-flow LV AD deranged the normal
profile of pulsatile cardiac hemodynamics. As continuous support increased, the peak
left ventricular pressure (57±9 mmHg) dropped below the arterial diastolic pressure
(67±6 mmHg). Insufficient preload was available to eject through the aortic valve, which
did not open. As a result, the workload of the heart was dramatically reduced to values
that are not observed in bovids. As in normal animals, during continuous unloading of
the failing left ventricle, cardiac workload decreased, and myocardial vascular resistance
increased with a signiticant dose-dependent response. However, in contrast to normal
animals, during full support of animals with chronic heart failure, a significantly
increased diastolic blood pressure increased coronary perfusion despite dramatically
reduced myocardial metabolic demands. Importantly, the ratio of blood supply/demand
improved to values observed in normal control animals. These findings suggested that in
animals with chronic heart failure, a coronary reserve was not present and the heart may
have been operating at an insufficient ratio of blood supply/demand. The lack of a
change in vascular resistance and blood flow in the epicardial region during any level of
support further suggested that coronary vasoreactivity was impaired such that coronary
vasoconstriction did not occur, thereby ensuring adequate myocardial blood flow.

Partial support provided inadequate reduction of myocardial metabolism and
augmentation of diastolic blood pressure to improve the blood supply/demand
relationship. As a result, it seems that partial support may be inappropriate as the first
step in a multistep protocol to provide prolonged unloading toward myocardial recovery.
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Figure 13, Left Myocardial Map: In animals with ischemic heart failure, the left ventricle
operated at a reduced myocardial blood supply demand/demand ratio. Center Myocardial
Maps: Immediately after the implantation of an LV AD, partial support was ineffective at
rebalancing this relationship. Right Myocardial Map: However, full support normalized
the blood supply/demand relationship throughout the left ventricle and interventricular
septum.

Yet, full support of the failing left ventricle with an L V AD did restore a normal
myocardial blood supply/demand relationship (Figure 13). This novel finding suggests
that during the immediate postoperative period after the implantation of an LV AD, the
heart should be fully unloaded.

This conclusion should be interpreted with caution. Full support decreased the
HR x L VP peak systolic, an index of myocardial metabolic demand, to values that are not
encountered in bovids. In heart failure, moderate reductions in metabolic demands are
likely favorable, especially if the goal of treatment is myocardial recovery. However, the
optimal reduction in cardiac metabolism which allows the heart to rest while still
maintaining a partial workload has not been established, and excessive myocardial
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unloading in which the heart performs too little work may induce myocardial atrophl9, 30
and fibrosis 3l , 32.

Nonetheless, full support of the failing left ventricle by a continuous-flow LV AD has
resulted in myocardial recovery9. Yet, myocardial recovery has most frequently been
reported in patients that received pulsatile ventricular assistance5, 6. This critical finding
suggests that variations in the ventricular pressure-volume relationship and cardiac
workload may be important to reverse myocardial remodeling during heart failure. It is
unclear how variations in stroke work affect myocardial remodeling. However, it is
known that normal ventricular geometry depends on a consistent physiologic pressurevolume relationship. As we have demonstrated, partial unloading preserved this
relationship and permitted ejection though the aortic valve on every beat. These findings
suggest a mechanism by which low native-heart volume output and loss of myocardial
mechanical stretch may cause the heart to become a stiff and non-functional chamber.

Therefore, it remains to be determined how long temporary full support with a
continuous-flow LVAD is necessary before a transition to partial support is safe. Only
after interrupting the progressive hemodynamic deterioration of heart failure, normalizing
autonomic tone, and n:storing normal end-organ perfusion may the heart regain adequate
function and be weaned to a partial-support mode. At that time, the reinstatement of a
partial cardiac workload may prevent unfavorable remodeling that is characteristic of
prolonged complete unloading of the failing left ventricle. Long-term studies in our
model of chronic, ischemic heart failure are necessary to determine the length of full
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support prior to a transition to partial support that may prevent myocyte atrophy and left
ventricular fibrosis.

Effects on the Arterial System and Emerging Novel Pathologies
In the arteries of animals with chronic heart failure, full support of the left ventricle with
a continuous-flow LV AD deranged the normal profile of pulsatile arterial
hemodynamics. As continuous support increased, arterial diastolic pressure increased
significantly, and the AoP pulse collapsed to 5± 1 mmHg, a value which is not compatible
with life in mammals in nature

28

.

This finding has important implications for prolonged

LV AD therapy. Although increased diastolic blood pressure favors an increase in
myocardial and end-organ blood flow, chronic non-pulsatile blood flow may alter the
structure and physiological reactivity of arteries and arterioles. As the AoP pulse decreases,
vascular resistance increases. Indeed, we have reported acute increases in vascular
impedance in human patients in response to continuous-flow mechanical circulatory
support 106 . Acute physiologic studies in canines have demonstrated that systemic
vascular resistance is inversely related to AoP pulse and that systemic vascular resistance
during non-pulsatile circulation is as much as 134% of that during pulsatile circulation 107 .
Chronic studies in goats undergoing prolonged, non-pulsatile cardiopulmonary bypass
demonstrated atrophic changes in the tunica media of the aorta that included decreased
total smooth muscle volume, reduced cell size, changes in the constituent volume ratio of
collagen and elastin, and decreased number of myofilaments and chromatin in smooth
muscle cells 108. Additional studies in the same model demonstrated decreased arterial
. . response to norepmep
. hr'me 109 and ph eny Iephr'me 110 and suggeste d that
vasoconstrIctIve
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non-pulsatile blood flow affects vascular reactivity. Overall, the net effect of prolonged
non-pulsatile blood flow is endothelial remodeling, loss of arterial reactivity, and
extracellular matrix remodeling, which alter arterial visco-elastic performance
characteristics and produces stiff and unresponsive arteries.

It may be speculated that changes to the endothelium may contribute to novel pathologies

observed in patients with prolonged non-pUlsatile blood flow. For example, recent
reports have documented an increased incidence in refractory diastolic hypertension57, 58,
ischemic and hemorrhagic stroke 86 , acquired von Willebrand disease 87 , 88, and
gastrointestinal arteriovenous malformations and bleeding
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in patients with continuous-

flow LV ADs. These cardiovascular pathologies likely share a common etiology related
to the absence of pulsatile stretch of arteries and/or the influence of high, pulseless shear
stress on the endothelium. Although causality and mechanism remain to be determined,
effects of prolonged diastolic hypertension with a narrow pulse pressure on the
vasculature (and heart) may be a limiting factor in long-term patient outcomes.

Clinical Implications
These findings have important clinical implications for device development, selection,
operation, and weaning. If combined, the benefits of a full-support device implanted with
a minimally invasive surgical approach may expand the target patient population for
myocardial recovery with an LVAD. As LV ADs are miniaturized, limited thoracotomy,
subxiphoid access, thoracic keyhole access, placement of surface devices, or
percutaneous implantation may permit initial full support which is later reduced to partial
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support. Minimally invasive implantation may increase acceptance by patients and
physicians who are more likely to refer patients for less-invasive surgical therapies 71 •
Earlier intervention in less-sick patients may increase the public-health impact of
mechanical circulatory support. Additionally, these operative approaches often do not
require cardiopulmonary bypass 103. As a result, less postoperative coagulopathy may
reduce postoperative bleeding and blood transfusions which playa role in right
ventricular dysfunction and infection with LVADsI04.

In summary, partial support with a continuous-flow LV AD is feasible and may preserve a
more normal cardiac and systemic arterial hemodynamic profile. However, partial
support may not be appropriate as the initial step in the clinical management of patients
with chronic heart failure. Only after a period of full support may the level of support be
reduced. Additional studies are needed to determine the duration of full support
necessary prior to prolonged partial support.
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CHAPTER VII

SUMMARY AND FUTURE RESEARCH DIRECTIONS

I. Summary of Findings

1)

Left main coronary artery microembolization induced chronic, ischemic
heart failure in calves. A stable and reproducible large-animal model of
chronic heart failure is possible with many phenotypic similarities to clinical
heart failure.

2)

In normal animals and animals with chronic heart failure, full but not partial
support with a continuous-flow LVAD deranged the physiological profile of
pulsatile cardiac and arterial hemodynamics.

3)

In normal animals, neither full nor partial support with a continuous-flow
L VAD affected the myocardial blood supply/demand relationship. However,
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in animals with chronic heart failure, full but not partial support normalized
the myocardial blood supply/demand relationship.

4)

Divergent results were observed between normal animals and animals with
chronic heart failure. Normal animals do not reproduce the complex
pathophysiological presentation of chronic heart failure and are not ideal for
validation and proper translation of mechanical circulatory support
strategies into clinical practice.

In order to translate basic scientific findings from the bench into the clinic, an appropriate
and clinically relevant large-animal model is necessary. We have developed a bovine
model of chronic, ischemic heart failure that reproduces the complex pathophysiological
presentation of functional, neurohormonal, and architectural derangements that are
typical in chronic heart failure. This model is relevant for preclinical testing of cardiac
devices and other translational therapies.

In this model, complete unloading of the failing left ventricle rebalanced the myocardial
blood supply/demand relationship. However, full-support with a continuous-flow LVAD
dramatically changed cardiac and systemic arterial hemodynamics, which may have longterm consequences sueh as myocardial and arterial remodeling.

In contrast, partial support was unable to normalize the blood supply/demand
relationship. Yet, partial support augmented systemic flows and preserved a normal
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profile of pulsatile hemodynamics in which the aortic valve opened on every beat.
Accordingly, why not combine the two modes of support? Our findings suggest that in
the immediate postop~:rative period after the implantation of an LV AD, complete
unloading of the failing left ventricle will rebalance the myocardial blood supply/demand
relationship. After a period of full support, it may be effective to reduce support and
restore native pulsatility.
Chronic studies are necessary to determine whether a transition to partial support may
prevent myocardial atrophy and fibrosis that is seen with prolonged full support while
still maintaining adequate end-organ blood flow. These studies should not be performed
in normal animals. Our bovine model of chronic, ischemic heart failure is appropriate for
such a study.
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II. Future Directions

Recent international experience with continuous-flow devices has progressively
improved clinical outcomes and the quality of life of patients that receive mechanical
circulatory support. New databanks for implantable cardiac devices such as
INTERMACS will increase this trend. As devices are miniaturized for earlier support
with less-invasive operative approaches, the incidence and prevalence of long-term
mechanical circulatory support is likely to increase globally.

Less-invasive surgical approaches and strategies oflong-term partial unloading of the
heart must be further investigated and refined. Invasive full-support devices may still be
reserved as a final treatment option for patients with life-threatening, end-stage heart
failure as a bridge to heart transplantation or as a destination therapy. In contrast, lessinvasive partial-support devices may prove successful for the management of less-severe
heart failure and relieve heart transplantation waiting lists as a destination therapy or as a
bridge to myocardial recovery. Partial-support devices may interrupt the progressive
hemodynamic deterioration of heart failure, improve symptoms and quality of life,
promote reverse myocardial remodeling, and allow for device explantation in select
patients.

With these goals in mind, additional chronic studies on effects of full and partial support
are needed to investigate mechanisms of pathological remodeling, reverse myocardial
remodeling, functional myocardial recovery, and pathophysiological responses to
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mechanical circulatory support. The mechanisms of histological changes in the
myocardium and conduit arteries are largely unknown. Endothelial cells are affected by
altered pulsatility and shear stress, but the role(s) of the endothelium in remodeling
processes are unknown. Similarly, angiogenesis is dependent on pulsatility and shear
stress and may be affected by systemic flow alterations with a continuous-flow LVAD.

Interactions between the autonomic nervous system and flow alterations with a
continuous-flow LV AD have not been defined but likely include altered baroreceptor
reflex sensitivity, catecholamine release, and arterial tone. These processes, which are
influenced by hemodynamic alterations, may affect end-organ blood flow, functional
capacity, and potential for recovery.

Going forward, experiments may be designed in which animals receive prolonged partial
or full support (or a combination of the two) with a continuous-flow LV AD. In these
studies it will be possible to further understand acute and chronic responses to
continuous-flow mechanical circulatory support.

Our model of chronic, ischemic heart failure is an appropriate and clinically relevant
heart failure substrate. Chronic studies will assist to further understand basic pulsatile
physiology as well as to define the clinical utility of partial support toward myocardial
recovery.

84

Ultimately, proper patient selection will be critical to achieve success with any device.
Device therapy should be tailored to patient needs. As such, careful examination of
preclinical and clinical experiences with current and future generations of implantable
devices will determim! the relative utility for different strategies of mechanical
circulatory support.
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